PROTOCOL: SHP465-112
TITLE: A Phase 1 Open-label Study of the Safety, Tolerability, and 
Pharmacokinetics of d-and l-Amphetamine after Multiple Daily Doses
of SHP465 6.25 mg Administered in Children Aged 4 to 5 years wit h 
Attention-Deficit/Hyperactivity Disorder
DRUG: SHP465
IND: 66,[ADDRESS_40577] NO.: Non-EUDRACT
SPONSOR: Shire Development LLC300 Shire Way, Lexington, MA [ZIP_CODE] US
PRINCIPAL/COORDINATINGINVESTIGATOR:TBD
PROTOCOL HISTORY:Original Protocol: [ADDRESS_40578] 
(marketed or investigational) does not meet expectations (eg, ina dequate or faulty closure, 
product contamination) or that the product did not meet the specifications defined in the 
application for the product (eg, wrong product such that the label and contents are different products). For instructions on reporting AEs related to product  complaints, refer to Section 8.
Please use the following information as applicable to report the Product Quality Complaint:
Origin of Product Quality Complaint E-mail Address
North and South America
Telephone numbers (provided for reference if needed):
Shire, Lexington, MA (US)

CONFIDENTIAL Page [ADDRESS_40579] Background and Clinical Information ................. .......................................25
2 STUDY OBJECTIVES AND PURPOSE ................................... ...........................................26
2.1 Rationale for the Study..................................... ........................................................26
2.2 Study Objectives ............................................ ..........................................................26
2.2.1 Primary Objective ......................................... .............................................26
3 STUDY DESIGN ...................................................................................................................26
3.1 Study Design ................................................ ............................................................26
3.2 Duration and Study Completion Definition .................... .........................................27
3.3 Sites and Regions .....................................................................................................28
4 STUDY POPULATION.............................................. ...........................................................28
4.1 Inclusion Criteria......................................................................................................284.2 Exclusion Criteria.......................................... ...........................................................29
4.3 Reproductive Potential .............................................................................................314.4 Discontinuation of Subjects .....................................................................................31
4.4.1 Management of Blood Pressure and Pulse During the Study....................31
[IP_ADDRESS] Systolic and Diastolic Blood Pressure .......................................................[IP_ADDRESS] Pulse...........................................................................................................32
4.4.2 Reasons for Discontinuation......................................................................334.4.3 Subjects “Lost to Follow-up” Prior to Last Scheduled Visit .....................[ADDRESS_40580] Compliance..................................................................................................39
7 STUDY PROCEDURES........................................................................................................40
7.1 Study Schedule.........................................................................................................40
7.1.1 Screening and Washout Period ..................................................................41
7.1.2 Treatment Period.......................................... ..............................................42
7.1.3 Follow-up Period .......................................... .............................................42
7.1.4 Additional Care of Subjects after the Study ..............................................43
7.2 Study Evaluations and Procedures ............................ ...............................................43
7.2.1 Demographic and Other Baseline Characteristics ............. ........................43
[IP_ADDRESS] Mini International Neuropsychiatric Interview for Childr en and 
Adolescents (MINI-KID) .......................................................................43
[IP_ADDRESS] Clinical Global Impressions............................. ..........................................44
[IP_ADDRESS] The ADHD-Rating Scale-5................................. .......................................44
7.2.2 Safety .................................................... .....................................................44
[IP_ADDRESS] Medical and Medication History ...............................................................45
[IP_ADDRESS] Physical Examination (Including Height and Weight) ..............................[IP_ADDRESS] Adverse Event Collection ..........................................................................[IP_ADDRESS] Vital Signs............................................. .....................................................46
[IP_ADDRESS] Clinical Laboratory Evaluations ......................... .......................................47
[IP_ADDRESS] Drug and Alcohol Screen................................. ..........................................48
[IP_ADDRESS] Electrocardiogram......................................................................................[IP_ADDRESS] Columbia-Suicide Severity Rating Scale.................. .................................49
[IP_ADDRESS] Children’s Sleep Habits Questionnaire................... ...................................50
[IP_ADDRESS] Post Sleep Questionnaire ...........................................................................[IP_ADDRESS] Suitability of the Subject to Remain in the Study...... ................................50
7.2.3 Pharmacokinetic Procedures......................................................................51
[IP_ADDRESS] Blood Sample Collection and Handling Procedures..................................[IP_ADDRESS] Shipment of Plasma Pharmacokinetic Samples.........................................52
CONFIDENTIAL Page 8 Shire
Protocol SHP465-112 15 Sep 2017
[IP_ADDRESS] Plasma Drug Assay Methodology .............................................................[ADDRESS_40581], Ethics Comm ittee, 
and Site Reporting......................................................................................58
9 DATA MANAGEMENT AND STATISTICAL METHODS....................... ........................59
9.1 Data Collection.........................................................................................................599.2 Clinical Data Management.................................... ...................................................59
9.3 Statistical Analysis Process................................ ......................................................59
9.4 Planned Interim Analysis, Adaptive Design, and Data Monitori ng Committee......60
9.4.1 Data Monitoring Committee......................................................................60
9.5 Sample Size Calculation and Power Considerations............ ....................................60
9.6 Study Population ............................................ ..........................................................61
9.7 Pharmacokinetic Analyses .......................................................................................61
9.7.1 Pharmacokinetic Analysis.................................. ........................................61
[IP_ADDRESS] Statistical Analysis of Pharmacokinetic Parameters...... ............................62
9.8 Safety Analyses ........................................................................................................62
10 SPONSOR’S AND INVESTIGATOR’S RESPONSIBILITIES ...........................................63
10.1 Sponsor’s Responsibilities .......................................................................................63
10.1.1 Good Clinical Practice Compliance........................ ...................................63
10.1.2 Public Posting of Study Information...................... ....................................63
10.1.3 Submission of Summary of Clinical Study Report to Compete nt 
Authorities of Member States Concerned and Ethics Committees... .........64
CONFIDENTIAL Page 9 Shire
Protocol SHP465-112 15 Sep 2017
10.1.4 Study Suspension, Termination, and Completion............ ..........................64
10.2 Investigator’s Responsibilities .................................................................................64
10.2.1 Good Clinical Practice Compliance........................ ...................................64
10.2.2 Protocol Adherence and Investigator Agreement ............ ..........................64
10.2.3 Documentation and Retention of Records .................................................65
[IP_ADDRESS] Case Report Forms.....................................................................................65
[IP_ADDRESS] Recording, Access, and Retention of Source Data and Study 
Documents...................................................... ........................................65
[IP_ADDRESS] Audit/Inspection....................................... ..................................................66
[IP_ADDRESS] Financial Disclosure...................................................................................[ADDRESS_40582] and Infectious Disease Regulations and Legislation ................66
10.3 Ethical Considerations..............................................................................................66
10.3.1 Informed Consent/Assent.................................. .........................................[ADDRESS_40583] or Ethics Committee ........... ...........................67
10.4 Privacy and Confidentiality......................................................................................6710.5 Study Results/Publication Policy ........................... ..................................................68
11 REFERENCES .......................................................................................................................7012 APPENDICES ........................................................................................................................73
Appendix 1 PROTOCOL HISTORY ..................................... .......................................74
Appendix 2 DIAGNOSTIC CRITERIA/DISEASE CLASSIFICATION........... ..........75
Appendix 2.1 DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL 
DISORDERS, FIFTH EDITION CRITERIA.............................. ..............75
Appendix 2.2 BOYS’ STATURE-FOR-AGE AND WEIGHT-FOR-AGE 
PERCENTILES .................................................... .....................................77
Appendix 2.3 BLOOD PRESSURE LEVELS FOR BOYS BY [CONTACT_38868].............................................. ..............................78
Appendix 2.4 GIRLS’ STATURE-FOR-AGE AND WEIGHT-FOR-AGE 
PERCENTILES .................................................... .....................................[ADDRESS_40584] OF TABLES
Table 1: Schedule of Assessments for Rich Pharmacokinetic Sampling Portion .......20
Table 2: Schedule of Assessments for Sparse Pharmacokinetic Sampling 
Portion ........................................................ ...................................................22
Table 3: Common Excluded Treatments and Associated Washout Period 
Relative to Baseline Visit ..............................................................................35
Table 4: Volume of Blood to be Drawn from Each Subject (Rich 
Pharmacokinetic Sample Subset) ................................. .................................53
Table 5: Volume of Blood to be Drawn from Each Subject (Sparse 
Pharmacokinetic Sample Subset) ................................. .................................53
Table 6: Estimates of Clearance and Volume of Distribution for d-
Amphetamine and l-Amphetamine................................................... .............60
CONFIDENTIAL Page 11 Shire
Protocol SHP465-112 15 Sep 2017
ABBREVIATIONS
ADHD attention-deficit/hyperactivity disorder
ADHD-RS-5 Attention-Deficit/Hyperactivity Disorder Rating Scale- 5
AE adverse event
AUC 0-∞ area under the curve extrapolated to infinity
AUC last area under the curve from the time of dosing to the last measura ble concentration
AUC 0-t area under the curve from time [ADDRESS_40585] time point of sample collection
AUC tau area under the concentration curve over the dosing interval (24 hours), at steady state 
BMI body mass index
CGI-S Clinical Global Impressions – Severity of Illness
CL/F total body clearance for extravascular administration
Cmax maximum concentration occurring at t max
CSHQ Children’s Sleep Habits Questionnaire
Ctrough trough plasma concentration (the predose concentrations collect ed at steady state)
CRA clinical research associate
CRC clinical research centerCRF case report formCRO contract research organization
C-SSRS Columbia-Suicide Severity Rating Scale
DMC data monitoring committeeDSM-5 Diagnostic and Statistical Manual of Mental Disorders, 5th EditionEC ethics committeeECG electrocardiogramFDA Food and Drug Administration
GCP Good Clinical Practice
HIPAA Health Insurance Portability and Accountability ActIB investigator’s brochureICH International Council for HarmonisationIRB institutional review boardLAR legally authorized representative
MINI-KID Mini International Neuropsychiatric Interview for Childr en and Adolescents
PK pharmacokinetic(s)
PSQ Post Sleep QuestionnaireSAE serious adverse eventSAP statistical analysis planT3 tri-iodothyronineT4 thyroxine
CONFIDENTIAL Page 12 Shire
Protocol SHP465-112 15 Sep 2017
t1/2 terminal half-life
TEAE treatment-emergent adverse event
tmax time of maximum observed concentration sampled during a dosing interval
US [LOCATION_002]
VF/ss apparent volume of distribution at steady state
Vz/F volume of distribution associated with the terminal slope fol lowing extravascular 
administration
z the first order rate constant associated with the terminal phas e of elimination
CONFIDENTIAL Page 13 Shire
Protocol SHP465-112 15 Sep 2017
STUDY SYNOPSIS
Protocol number: SHP465-112 Drug: SHP465, mixed salts of a single-entity amphetamine
Title of the study: A Phase [ADDRESS_40586] ered in Children Aged 4 to 5 years with 
Attention-Deficit/Hyperactivity Disorder
Number of subjects (total and for each treatment arm): Approximately 24 subjects are expected to be enrolled to 
ensure that 10 subjects will complete the rich pharmacokinetic (PK) sampling portion of the study and an additional 
[ADDRESS_40587] 3 of the 10 subjects 
in the sparse PK sampling portion of the study expected to comp lete the study are females.
Investigators: Multicenter study
Sites and Regions: Approximately 10 sites in the [LOCATION_002] will participate in this study
Study period (planned): 2017-2018 Clinical phase: 1
Objectives:
Primary: To evaluate the pharmacokinetics (PK), safety, and tolerability of SHP465 in children aged 4 to 5 years 
with attention-deficit/hyperactivity disorder (ADHD) after SHP465 multiple daily doses of 6.25 mg.
Rationale:The proposed clinical study is being conducted to provide informa tion on SHP465 PK, safety, and tolerability after 
[ADDRESS_40588], dose, and mode of administration:
There will be one SHP465 dose level of 6.25 mg used in this stud y.
SHP465 6.25 mg will be given once daily for 28 days (±1 day) at 8:00 AM(±1 hour).
Investigational product will be taken by [CONTACT_38869] 1 tablespoon of applesauce and ingesting the entire mixture immediately without chewing.
Methodology:
The study will be a Phase 1, open-label, multiple-dose, PK, safety, and tolerability study in children aged [ADDRESS_40589]. Once the required number of subje cts is achieved, enrollment in the sparse PK sampling 
group will begin.
Screening Period (Includes Washout Period)
Subjects will be assessed for eligibility during the screening period. The duration of the screening period will be a 
maximum of [ADDRESS_40590] on Day 1 of Week 1 
(washout period).
Following the screening visit, eligible subjects will return to the clinical research center (CRC) on Day [ADDRESS_40591] be repeated at baseline (prior to the first dose of investigational product on Day 1 of Week 1): vital signs, 
clinical laboratory evaluations, blood pressure, electrocardiog rams (ECGs), weight, and height. The physical 
examination will be abbreviated with a review of the following body systems: general appearance, respi[INVESTIGATOR_696], and 
cardiovascular. 
 
CONFIDENTIAL Page [ADDRESS_40592] will receive SHP465 6.25 mg as a daily dose for 28 days (±1 day).
PK Sample Collection
Subjects should be adequately hydrated before blood draws. Caffeinated drinks should be avoided. Details on fasting 
and hydration are provided in Section 6.2.2.
Rich PK Sample Scheme (9 Samples/Subject) Collection
Predose PK samples will be collected on Day 1 of Week 1, and serial blood samples for PK analysis will be drawn 
prior to dosing on Day 7 of Week 4 (within 60 minutes prior to dosing) and up to [ADDRESS_40593].
On Day 7 of Week 4, subset of subjects in the rich PK sampling portion will be required to remain at the CRC 
through 8 hours postdose. Following completion of the 8-hour PK  sample collection, per investigator’s discretion, 
subjects will have the option to remain at or leave the CRC. If they leave the CRC, subjects will either return to theCRC on Days 7, 8, and [ADDRESS_40594] return to the clinic for the 48-hour blood
sample collection.
Sparse PK Sample Scheme (4 Samples/Subject) Collection
Predose PK samples will be collected on Day 1 of Weeks 1 to 3 a nd on Day 8 of Week 4 (24 hours after dosing on 
Day 7 of Week 4) for subjects in the sparse PK sampling subset.
The end-of-study assessments will be performed at the last clin ic visit: on Day 9 of Week 4 (approximately [ADDRESS_40595]) for subjects in  the rich PK sampling portion and on Day 8 of Week 4 
(approximately [ADDRESS_40596]) for subjects in the sparse PK sampling portion 
of the study.
Follow-up
At the last clinic visit, subjects and their parent/legally authorized representative (LAR) will be offered to rollover 
into the SHP465-308 study. If subjects agree and their parent/L AR signs the informed consent form, this will end 
their participation in the SHP465-[ADDRESS_40597] (study visit/telephone call) will be conducted. For tho se subjects with ongoing adverse events (AEs), a 
mandatory in-person follow-up visit at the CRC will occur 7 day s (±2 days) following the subject’s last dose of 
investigational product to collect information on any ongoing or  new AEs, serious AEs (SAEs), or concomitant 
medications, as appropriate.
At the investigator’s discretion, for those subjects with no ongoing AEs at the time of the last scheduled assessment, 
a telephone call initiated by [CONTACT_38870]-person follow -up visit at the CRC will occur 7 days (±2 days) 
following the subject’s last dose of investigational product to collect information on any new AEs, SAEs, or 
concomitant medications, as appropriate.
Inclusion and exclusion criteria:
Inclusion Criteria
The subject will not be considered eligible for the study without meeting all of the following criteria (including test 
results).
1. Subject is a male or female aged [ADDRESS_40598] and parent/LAR are willing and able to fully comply w ith all of the testing and requirements defined in
the protocol. Specifically, the parent/LAR must be available at  approximately 8:00 
AM(±1 hour) to administer
the dose of investigational product at the time points specified in the protocol.
3. Subject’s parent/LAR must sign the informed consent form, and th ere must be documentation of assent (if
applicable) by [CONTACT_38871] E6 (2016) and any updates, and applicable regu lations, before starting any study-related
procedures.
CONFIDENTIAL Page [ADDRESS_40599] satisfies the following ADHD criteria during the scre ening period:
Meets the Diagnostic and Statistical Manual of Mental Disorders,  Fifth Edition criteria for a primary
diagnosis of ADHD (any subtype) based on a detailed psychiatric  evaluation using the Mini International
Neuropsychiatric Interview for Children and Adolescents
Has an ADHD Rating Scale-5 Child, Home Version Total Score of ≥28 for boys and ≥24 for girls
Has a Clinical Global Impressions – Severity of Illness score ≥4.
5. Subject functions at an age-appropriate level intellectually, as determined by [CONTACT_093].
6. Subject has undergone an adequate course of nonpharmacologica l treatment ORthe subject has a severe
enough condition to consider enrollment without undergoing prior nonpharmacological treatment, based on the
investigator’s judgment ORhas never taken ADHD medication ORhas taken ADHD medication with
unacceptable efficacy and/or tolerability.
7. Subject has the ability to take investigational product by [CONTACT_38872].
8. Subject has lived with the same parent/LAR for at least 6 month s.
Exclusion Criteria
Subjects are excluded from the study if any of the following exclusion criteria are met:
1. Prior enrollment or participation in the study.
2. Subject has a documented allergy, hypersensitivity, or intole rance to amphetamine or to any excipi[INVESTIGATOR_38846].
3. Subject cannot swallow a pi[INVESTIGATOR_38847]/or applesauce, or has an al lergy to applesauce.
4. Subject is currently taking or has taken ADHD medication with acceptable efficacy and tolerability.
5. Subject has taken ADHD medication within [ADDRESS_40600] has used any medication (including over-the-counter, h erbal, or homeopathic preparations) within
[ADDRESS_40601] or  5-half-lives, whichever is longer, with the
exception of the following:
Thyroid medication
Intermittent use of nonsteroidal anti-inflammatory drugs or ace taminophen for minor aches and pains
As needed use of a beta-agonist s inhaler for m ild asthma or exer cise induced bronchospasm
Over-the-counter nonsedating antihistamines such as fexofenadin e (ALLEGRA®, [COMPANY_011]), loratadine
(CLARITIN®, Schering-Plough), or cetirizine hydrochloride ( ZYRTEC®, McNeil-PPC) for allergies.
Subject has continuously used oral corticosteroids ≥[ADDRESS_40602]
dosing. If continuous use was <[ADDRESS_40603]:
Subject has used an investigational product.
RIf the elimination half-life of the previous study’s investigat ional product was less than [ADDRESS_40604] dose of SHP465.
RIf the elimination half-life of the previous study’s investigat ional product was greater than [ADDRESS_40605] screening
visit based on the investigator’s judgment. A single retest of labo ratory parameters is allowed based on the
investigator’s judgment.
12. Subject has Marfan’s syndrome.
13. Subject has a blood pressure ≥95th percentile for age, sex, and height at the screening visit.
14. Subject has a height 5th percentile for age and sex at the first screening visit.
15. Subject has a weight 5th percentile for age and sex at the first screening visit.
16. Subject has current abnormal thyroid function test results, defined as abnormal thyroid-stimulating hormone,
thyroxine, and tri-iodothyronine at the first screening visit. Treatment with a stable dose of thyroid medication
for at least [ADDRESS_40606] has a history of seizures (other than infantile febr ile seizures).
18. Subject has a current, controlled (requiring medication or therapy) or uncontrolled, comorbid psychiatric
disorder including but not limited to any of the following como rbid Axis I disorders and Axis II disorders:
Post-traumatic stress disorder or adjustment disorder
Bipolar disorder, psychosis/schizophrenia, or positive family h istory of these disorders in first- or
second-degree relatives
Pervasive developmental disorder
Obsessive-compulsive disorder
A serious tic disorder, or a family history of Tourette disorder
Substance abuse or dependence disorder
Any other disorder that in the opi[INVESTIGATOR_38848]465 or amphetaminetreatment or confounds safety assessments.
19. Subject is currently considered a suicide risk in the opi[INVESTIGATOR_3078] n of the investigator, has previously made a suicide
attempt, or has a prior history of or is currently demonstrating active suicidal ideation.
20. Subject has a history of physical, sexual, or emotional abuse.
21. Subject has a primary sleep disorder (eg, sleep apnea, narcolepsy).22. Subject has a history or is currently diagnosed with an eati ng disorder.
23. Subject has a clinically important abnormality on the urine drug and alcohol screen (excluding the subject’s
current ADHD stimulant, if applicable) at the first screening visit.
24. Subject lives with anyone who currently abuses stimulants or cocaine, based on the investigator’s judgment.
25. Subject has a concurrent chronic or acute illness (such as s evere allergic rhinitis or an infectious process
requiring antibiotics), disability, or other condition that might confound the results of safety assessments
conducted in the study or that might increase risk to the subje ct.
26. Subject has any additional condition(s) such as any signific ant illness or unstable medical condition that, in the
investigator's opi[INVESTIGATOR_1649], would prohibit the subject from completing the study and /or could lead to difficulty
complying with the protocol.
CONFIDENTIAL Page [ADDRESS_40607] involvement in the study:
Each subject’s maximum duration of participation is expected to  be approximately 9 weeks. The study will be
completed in approximately 12 months.
Screening period:
A maximum of [ADDRESS_40608]
If applicable, this includes a washout period that is to start [ADDRESS_40609].
Treatment Period: Total duration for the treatment period is ap proximately 30 days for subjects in the rich
PK sampling portion of the study and 29 days for subjects in the sparse PK sampling portion of the study.
Follow-up contact: [CONTACT_38873], subjects and their  parent/LAR will be offered to rollover into the
SHP465-308 study. If subjects agree and their parent/LAR signs the informed consent form, this will end their
participation in the SHP465-[ADDRESS_40610] will be conducted approximately 1 week (7 days [±2 days] ) following the last dose of investigational
product.
Sample size and power calculations :
To objectively justify the sample size for PK sampling and PK sampling scheme for this study, the following precision is recommended in the Food and Drug Administration gui dance, General Clinical Pharmacology: 
Considerations for Pediatric Studies for Drugs and Biological Pr oducts.
The sample size for traditional rich PK sampling for noncompartme ntal analysis is calculated to achieve 80% 
probability (power) , to assure the 95% confidence interval of the  point estimate of the geometric mean of clearance 
is within 60% to 140% of the estimate of the clearance. Althoug h the range (60%, 140%) is not symmetric to 1, the 
lower confidence interval bound is within (60%, 140%) (1/1.4=0. 714) as long as the upper bound is ≤1.4.
The available data in the following table are from Shire’s completed study (SHP465-111) with an ADHD pediatrics population and show the reported apparent clearance (CL/F) and v olume of distribution (V
z/F) for the 
d-amphetamine and l-amphetamine of SHP465 after oral administration of 12.5 mg in children aged 6 to 12 years 
and 25 mg in adolescents aged 13 to 17 years.
Estimates of Clearance and Volume of Distribution for G-Amphetamine and O-Amphetamine
CV (%)SHP465 12.5 mg
Children (6 to 12 years)SHP465 25 mg
Adolescents (13 to 17 years)
CL/F (L/h) V z/F (L) CL/F (L/h) V z/F (L)
d-Amphetamine 25.0 28.5 23.7 18.4
l-Amphetamine 26.9 32.2 28.4 22.0
CV=coefficient of variation  
Source: SHP465-[ADDRESS_40611] l-amphetamine variability of 32.2%, since it is numerically bigger. 
Applying the methods from the manuscript by [CONTACT_38874]., 2012, sa mple size estimations with related probability 
for corresponding coefficients of variation are provided as follows:
CV (%) Number of Subjects RequiredProbability of the Point Estimate 
Within the Prespecified Interval (%)
18.4 5 89
22.0 5 80
23.7 6 88
25.0 6 82
26.9 7 89
28.4 7 88
28.5 7 88
32.2 8 90
CV=coefficient of variation
Based on these data, the PK analysis will need at least 8 subjects in total to provide reliable PK parameter estimates.
Endpoints and statistical analysis :
Analysis Populations
The screened set will consist of all subjects who have provided informed consent.
The enrolled set will consist of all subjects who have been assigned a subject id entification number.
The safety set will consist of all enrolled subjects who have taken at least [ADDRESS_40612] of all subjects in the safety set for whom at leas t 1 postdose PK blood sample was collected.
Pharmacokinetic Endpoints
Pharmacokinetic parameters will be determined from the plasma c oncentration-time data for d-amphetamine and 
l-amphetamine by [CONTACT_38875]®WinNonlin®(Certara, Princeton, NJ) Version 6.4 or 
higher.
The PK parameters will include, but not be limited to:
AUC 0-∞ Area under the curve extrapolated to infinity
AUC 0-t Area under the curve from time [ADDRESS_40613] e collection
AUC 0-5 Area under the curve from time 0 predose to 5 hours postdose
AUC 5-t Area under the curve from time [ADDRESS_40614] time point of sample collection
AUC last Area under the curve from the time of dosing to the last measurable concentration
AUC tau Area under the concentration curve over the dosing interval (24 hours) at steady state
CL/F Total body clearance for extravascular administration
Cmax Maximum concentration occurring at t max
Ctrough Trough plasma concentration (the predose concentrations collected at steady state)
t1/2 Terminal half-life
tmax Time of maximum observed concentration sampled during a dosing i nterval
VF/ss Apparent volume of distribution at steady state
Vz/F Volume of distribution associated with the terminal slope following extravascular administration
 z The first order rate constant associated with the terminal phas e of elimination
CONFIDENTIAL Page 19 Shire
Protocol SHP465-112 15 Sep 2017
There will be no inferential statistical analysis of the PK dat a. Summary descriptive statistics (number of 
observations, mean, standard deviation, coefficient of variation, median, maximum, minimum and geometric mean) 
will be determined for all PK parameters. Plasma concentrations  at each nominal sampling time will also be 
summarized using descriptive statistics.
Safety Endpoints
Safety will be assessed by [CONTACT_3148]-emergent AEs (TEAEs), vital signs (systolic and diastolic blood pressure, pulse 
rate, respi[INVESTIGATOR_697], and body temperature), 12-lead ECGs, we ight, height, clinical laboratory tests (biochemistry, 
hematology, and urinalysis), Post Sleep Questionnaire (PSQ), an d a validated sleep questionnaire (Children’s Sleep 
Habits Questionnaire [CSHQ]).
Additionally, the Columbia-Suicide Severity Rating Scale (C-SSR S) scale will capture the safety of SHP465 related 
to suicidality.The safety endpoints will be summarized with descriptive statist ics for the safety set.
Baseline is defined as the last assessment prior to the first d ose of investigational product. Potentially clinically 
important findings will also be summarized or listed. The potentially clinically important values will be defined in 
the statistical analysis plan.
Weight, height, BMI, vital signs, ECG, PSQ, and CSHQ will be summarized. The C-SSRS results will be 
summarized and a listing of the C-SSRS data will be provided for  subjects with a positive response.
Adverse events will be coded using the agreed-upon version of th e Medical Dictionary for Regulatory Activities. 
The number of events, incidence, and percentage of TEAEs will be calculated overall, by [CONTACT_9313], and by 
[CONTACT_11702]. Treatment-emergent AEs will be further summariz ed by [CONTACT_38876]. Adverse events related to investigational product, AEs leading to withdrawal, SAEs, and deaths will be 
similarly summarized/listed.
CONFIDENTIAL Page 20 Shire
Protocol SHP465-112 15 Sep 2017
STUDY SCHEDULE
Table 1: Schedule of Assessments for Rich Pharmacokinetic Sampling Portion
Assessment DayScreening and Washout Week 1
to 3Week 4 Follow-upa
D -32
to D -8D -7
to D -1
WashoutD 1 D 2-7 D 1 D 2-6 D 7 D 8bD 9
/ETb
Treatment Week 4 Time Point (h) Predosec0 2 5 8 12 16 24 48
Informed Consent & Assent X
Inclusion/Exclusion Criteria X Xd
Demographics X
Medical & Medication History (Includes 
Prior Medications and Procedures)eX
Physical Examination X XfXfXgXh
Vital SignsiXX X X X Xh
WeightjXX X X Xh
HeightjX Xh
Biochemistry, Hematology, and Urinalysis X Xh
TSH, T4, and T3 X Xh
Urine Drug and Alcohol Screen X
12-lead ECGiXX X X Xh
C-SSRS Baseline Version X
C-SSRS Since Last Visit Version X X X Xh
MINI-KID X
ADHD-RS-5 Child, Home Version X
Clinical Global Impressions – Severity of IllnessX
CSHQ XX X X Xh
PSQ XX X X Xh
Eligibility Confirmation Xd
Investigational Product Dispensed X X
Investigational Product Administration XkXlXkXlXk,m
CONFIDENTIAL Page 21 Shire
Protocol SHP465-112 15 Sep 2017
Table 1: Schedule of Assessments for Rich Pharmacokinetic Sampling Portion
Assessment DayScreening and Washout Week 1
to 3Week 4 Follow-upa
D -32
to D -8D -7
to D -1
WashoutD 1 D 2-7 D 1 D 2-6 D 7 D 8bD 9
/ETb
Treatment Week 4 Time Point (h) Predosec0 2 5 8 12 16 24 48
Pharmacokinetic Sample Collection XnX XXXXXX X
Concomitant Medications X X X X X X X X X X X X X X XhX
Adverse Events X X X X X X X X X X X X X X XhX
ADHD-RS-5=Attention-Deficit/Hyperactivity Disorder Rating Scale -5; CRC=clinical research center; C-SSRS=Columbia-Suicide Sever ity Rating Scale; CSHQ=Children's Sleep 
Habits Questionnaire; D=day; ECG=electrocardiogram; ET=Early Ter mination; h=hours; MINI-KID=Mini International Neuropsychiatric Interview for Children and Adolescents; 
PSQ=Post Sleep Questionnaire; TSH=thyroid-stimulating hormone; T3=tri-iodothyronine; T4=thyroxine.
a Follow-up contact [CONTACT_38877] 1 week (7 day s [±2 days]) following the last dose of investigational product .
bDay 8 and Day 9 may be conducted on an out-patient basis.
cThese assessments should be performed within 2 hours prior to dose administration with the exception of the pharmacokinetic sa mple, which should be collected within 
60 minutes prior to dosing.
dInclusion/exclusion criteria and eligibility confirmation must be reviewed at the CRC on Day [ADDRESS_40615]’s psychiatric diagnosis and a lifetime histo ry of pharmacologic therapi[INVESTIGATOR_38849].
fA brief physical examination will be performed prior to dosing on Day 1.
gA brief physical examination will be performed prior to dosing on Day [ADDRESS_40616] 5  minutes prior to collecting vital signs (systolic and diastoli c blood pressure, pulse rate, respi[INVESTIGATOR_697], and body 
temperature). Subjects should be resting in a supi[INVESTIGATOR_21683] [ADDRESS_40617] should be resti ng for 15 minutes.
Blood pressure and pulse will be measured at each visit. Measur ements of blood pressure and pulse will be performed 3 times (wit h at least 2 minutes in between each 
collection) using the provided age-appropriate cuff. The average of each set of 3 measurements will be used to determine continued participation in the study.Temperature and respi[INVESTIGATOR_38850].
Measurement of blood pressure and pulse will be performed 3 times (with at least 2 minutes in between each collection) using the provided age-appropriate cuff.
jHeight and weight to be measured without shoes and with light c lothing using a stadiometer for height and calibrated scale for  weight.
kDosing will be done at the CRC.
lDosing will be done at the home.
mSubjects should fast for [ADDRESS_40618], ie, a single serving of cereal with up to 8 ou nces of skim milk. Starting at 4 hours postdose on Day 1, for lunch and dinner, subjects will receive a standardized 
moderate fat meal. Subjects will be allowed snacks starting after lunch.
nTo be sampled predose on Week 1 only.Whenever possible, the same individual should complete/rate con sistently the following scales and questionnaires as appropriate : ADHD-RS-5 Child, Home Version; Clinical 
Global Impressions - Severity of Illness; Post Sleep Questionnai re; and Children’s Sleep Habits Questionnaire.
CONFIDENTIAL Page 22 Shire
Protocol SHP465-112 15 Sep 2017
Table 2: Schedule of Assessments for Sparse Pharmacokinetic Sampl ing Portion
Assessment DayScreening and Washout Week 1 to 3 Week 4 Follow-upa
D -32
to D -8D -7 to D -1
WashoutD 1 D 2-7 D 1 D 2-7 D 8
/ET
Informed Consent & Assent X
Inclusion/Exclusion Criteria X Xb
Demographics X
Medical & Medication HistorycX
Physical Examination X XdXdXe
Vital SignsfXX X Xe
WeightgXX X Xe
HeightgXXe
Biochemistry, Hematology, and Urinalysis X Xe
TSH, T4, and T3 X Xe
Urine Drug and Alcohol Screen X
12-lead ECGfXX Xe
C-SSRS Baseline Version X
C-SSRS Since Last Visit Version X X Xe
MINI-KID X
ADHD-RS-5 Child, Home Version X
Clinical Global Impressions – Severity of Illness X
CSHQ XX X Xe
PSQ XX X Xe
Eligibility Confirmation Xb
Investigational Product Dispensed X X
Investigational Product Administration XhXiXhXi
Pharmacokinetic Sample Collection - Predose X X
Concomitant Medications X X X X X X XeX
Adverse Events X X X X X X XeX
ADHD-RS-5=Attention-Deficit/Hyperactivity Disorder Rating Scale -5; CRC=clinical research center; C-SSRS=Columbia-Suicide Sever ity Rating Scale; CSHQ=Children's Sleep 
Habits Questionnaire; D=day; ECG=electrocardiogram; ET=Early Te rmination; h=hours; MINI-KID=Mini International Neuropsychiatri c Interview for Children and Adolescents; 
PSQ=Post Sleep Questionnaire; TSH=thyroid-stimulating hormone; T3=tri-iodothyronine; T4=thyroxine.
aFollow-up contact [CONTACT_38877] 1 week (7 day s [±2 days]) following the last dose of investigational product.
bInclusion/exclusion criteria and eligibility confirmation must be reviewed at the CRC on Day 1 of Week 1.
CONFIDENTIAL Page 23 Shire
Protocol SHP465-112 15 Sep 2017
Table 2: Schedule of Assessments for Sparse Pharmacokinetic Sampl ing Portion
Assessment DayScreening and Washout Week 1 to 3 Week 4 Follow-upa
D -32
to D -8D -7 to D -1
WashoutD 1 D 2-7 D 1 D 2-7 D 8
/ET
cMedical and medication history will include a detailed description of the subject’s psychiatric diagnosis and a lifetime history of pharmacologic therapi[INVESTIGATOR_38851].
dA brief physical examination will be performed prior to dosing on Day [ADDRESS_40619] 5  minutes prior to collecting vital signs (systolic and diastoli c blood pressure, pulse rate, respi[INVESTIGATOR_697], and body 
temperature). Subjects should be resting in a supi[INVESTIGATOR_2547] f or at least [ADDRESS_40620] was previously referred to as SPD46 5; however, it is now being 
studied under the code of SHP465. The amphetamine salt combinat ion found in SHP465 is 
comprised of sulfate salts of dextroamphetamine and amphetamine, with dextroamphetamine 
saccharate and amphetamine aspartate monohydrate, which provide  a composite enantiomer ratio 
of 3:1 d-amphetamine to l-amphetamine.
SHP465 capsule contains 3 types of drug-releasing beads providi ng immediate release, pulsatile 
delayed release, and delayed sustained release of the mixed amp hetamine salts. The immediate 
release bead comprises a drug-layered sphere which releases rap idly in the stomach. The 
pulsatile delayed-release bead includes an additional pH sensit ive polymer coating which is 
insoluble under gastric pH conditions but is soluble above pH 5. 5, thereby [CONTACT_38878]. The delayed sustained-release bead includes a pH sensitive polymer coating with 
an additional coating of a sustained-release polymer; this combination begins releasing drug once 
the gastrointestinal track reaches pH 7.0 or above.
Amphetamines are noncatecholamine sympathomimetic amines with c entral nervous system 
stimulant activity. The primary mechanism of action is to incre ase synaptic concentrations of 
monoamine neurotransmitters, thereby [CONTACT_38879], dopaminergic 
neurotransmission in the central nervous system ( Heal et al., 2013 ). Amphetamine increases the 
availability of biogenic amines (primarily dopamine and norepin ephrine) in central nerve 
synapses through multiple actions, including stimulating neurotransmitter release into the nerve 
terminal and inhibiting reuptake from the synapse. These action s may be the basis of its 
therapeutic actions in attention-deficit/hyperactivity disorder  (ADHD); however, the mode of 
therapeutic action in ADHD is not known.
1.[ADDRESS_40621] etiology of ADHD is unknown. Extensive research has s uggested that neurotransmitter 
deficits ( Arnsten, 2001 ), genetics ( Arnsten, 2001 ; Brown, 2003 ), environment ( Kahn et al., 
2003), and perinatal complications ( Bhutta and Anand, 2002 ) may all be contributing factors. 
The hypothesized mechanism of action of effective medications i n ADHD is to raise 
neurotransmitter levels (specifically norepi[INVESTIGATOR_13027]/or dop amine, or their precursors) at the 
synapse either by [CONTACT_38880] ( Kratochvil et al., 
2003; Wang et al., 2007 ).
According to the Diagnostic and Statistical Manual of Mental Di sorders, ADHD has 3 subtypes: 
hyperactive/impulsive, inattentive, and combined, and individual s with ADHD may manifest 
considerably different symptomology depending on sex, disorder subtype, and the presence of 
comorbid disorders.
Compared with nonstimulants, stimulant medications (ie, amphetam ine or methylphenidate) 
produce the most robust improvements in symptom expression acro ss all age ranges 
(Spencer et al., 1996 ). 
CONFIDENTIAL Page [ADDRESS_40622] a rapid onset of action, within 1 hour to 2 hours of 
dosing, compared with nonstimulants (eg, atomoxetine), which can require dosing for up to 
4 weeks to 6 weeks to achieve maximal therapeutic benefit ( Wilens et al., 2002 ).
Nonpharmacologic measures (psychological, educational, and socia l) can also be beneficial, and 
psychosocial treatments for adults with ADHD have been studied ( Safren et al., 2004 ; Greenfield 
and Hechman, 2005 ). Comorbid psychiatric and learning disorders are common in ad ults with 
ADHD, and appropriate evaluation, diagnosis, and treatment are r ecommended ( Weiss and 
Murray, 2003).
Importantly, symptoms may not only manifest throughout the day.  Many patients continue to 
have residual symptoms lasting into the evening hours ( Greenfield and Hechman, 2005 ). Adult 
patients may benefit from symptom relief into the evening hours  for such activities as planning 
and organizing, or professional activities (eg, professional work at night), spousal/parental 
responsibilities, and driving. Similarly, impairments in nightt ime activities are recognized in the 
pediatric population, which may need coverage all day and into the evening as well (eg, to do 
homework and to participate in family/social activities).
The impairments in psychosocial academic and occupational funct ioning associated with ADHD 
may arise from underlying chronic deficiencies in executive fun ction ( Brown, 1996). In general, 
the term executive function is used to describe a set of cognitive abilities that control and 
regulate judgments and behaviors which are necessary for goal-d irected behavior; however, the 
specific definition of executive functioning varies and is debated. Understanding and treating executive functioning deficits is increasingly considered an un met medical need in ADHD. 
1.[ADDRESS_40623] been evaluated in 1641 subjects in 16 clinical studies, of which 
13 clinical studies were in adu lt subjects aged 18 years to 55 ye ars and 3 clinical studies were in 
pediatric subjects aged 6 years to 17 years. The SHP465 clinical de velopment program has 
shown that doses of 12.5 mg to 50 mg in adult subjects and 12.5 mg to 25 mg in pediatric 
subjects demonstrate a safety and efficacy comparable to the pr ofile reflected in class labeling 
for stimulant products approved in the [LOCATION_002] (US).
The pharmacokinetic (PK) profile of SHP465 is not affected if the capsule is consumed intact or 
if capsule contents are sprinkled onto a small amount of food ( ie, 1 tablespoon of applesauce) 
and then ingested. The PK properties of SHP465 are not affected  by [CONTACT_38881]. The PK 
properties between d-amphetamine and l -amphetamine are similar.
Acceptable safety and tolerability profiles observed were consi stent with the types of side effects
specified in stimulant class labeling in the US. Specifically, administration of SHP465 was associated with increases in blood pressure (mean increase appro ximately 2-4 mmHg) and heart 
rate (mean increase approximately 3-6 bpm), and treatment-emerg ent adverse events (TEAEs) of 
insomnia, decreased appetite, decreased weight, heart rate incr eased, and anxiety, as well as 
psychiatric events (eg, mania, suicidality).
CONFIDENTIAL Page [ADDRESS_40624] version of the SHP465 investigator’s brochure (IB) for the overall 
risk/benefit assessment and the most accurate and current inform ation regarding the drug 
metabolism, pharmacokinetics (PK), efficacy, and s afety of SHP465.
[ADDRESS_40625] on Day 1 of Week 1  (washout period). 
Following the screening visit, eligible subjects will return to  the clinical research center (CRC) 
on Day [ADDRESS_40626] be repeated at baseline (prior to th e first dose of investigational 
product on Day 1 of Week 1): vital signs, clinical laboratory e valuations, blood pressure, 
electrocardiograms (ECGs), weight, and height. The physical exa mination will be abbreviated 
with a review of the following body systems: general appearance , respi[INVESTIGATOR_696], and 
cardiovascular.
The PK of d-amphetamine and l-amphetamine will be evaluated in this study, according to the 
schedule in Table 1 (rich PK sample subset) and Table 2 (sparse PK sample subset). 
CONFIDENTIAL Page 27 Shire
Protocol SHP465-112 15 Sep 2017
Rich PK Sample Scheme (9 Samples/Subject) Collection
Predose PK samples will be collected on Day 1 of Week 1, and serial blood samples for PK 
analysis will be drawn prior to dosing on Day 7 of Week 4 (withi n 60 minutes prior to dosing) 
and up to [ADDRESS_40627].
On Day 7 of Week 4, subset of subjects in the rich PK sampling portion will be required to 
remain at the CRC through 8 hours postdose. Following completion of the 8-hour PK sample collection, per investigator’s discretion, subjects will have the option to remain at or leave the CRC. If they leave the CRC, subjects will either return to the C RC on Days 7, 8, and [ADDRESS_40628] return to the 
clinic for the 48-hour blood sample collection.
Sparse PK Sample Scheme (4 Samples/Subject) Collection
Predose PK samples will be collected on Day 1 of Weeks 1 to 3 and on Day 8 of Week 4 
(24 hours after dosing on Day 7 of Week 4) for subjects in the s parse PK sampling subset.
3.[ADDRESS_40629]’s maximum duration of participation is expected to  be approximately 9 weeks. The 
study will be completed in approximately 12 months.
Screening period:
A maximum of [ADDRESS_40630]
If applicable, this includes a washout period that is to start [ADDRESS_40631].
Treatment Period: Total duration for the treatment period is ap proximately 30 days for
subjects in the rich PK sampling portion of the study and 29 da ys for subjects in the sparse
PK sampling portion of the study.
Follow-up contact: [CONTACT_38873], subjects and their  parent/legally authorized
representative (LAR) will be offered to rollover into the SHP465 -308 study. If subjects agree
and their parent/LAR signs the informed consent form, this will end their participation in the
SHP465-[ADDRESS_40632] will be conducted approximately 1 week (7 days [±2 days]) f ollowing the last dose of
investigational product.
The Study Completion Date is defined as the date the final subj ect, across all sites, completes 
their final protocol-defined assessment. Please note that this includes the follow-up visit or 
contact, whichever is later. The Study Completion Date is used to ascertain timing for study 
results posting and reporting.
CONFIDENTIAL Page [ADDRESS_40633] and parent/LAR must participate in the informed consent/assent process, and the 
parent/LAR must provide written informed consent/assent before any procedures specified in the 
protocol are performed.
4.[ADDRESS_40634] will not be considered eligible for the study withou t meeting all of the following 
criteria (including test results):
1. Subject is a male or female aged [ADDRESS_40635] and parent/LAR are willing and able to fully comply w ith all of the testing and
requirements defined in the protocol. Specifically, the parent/ LAR must be available at
approximately 8:00 AM(±1 hour) to administer the dose of investigational product at the time
points specified in the protocol.
3. Subject’s parent/LAR must sign the informed consent form, and t here must be
documentation of assent (if applicable) by [CONTACT_38882] (ICH) Good Clinical Practice (CGP) Gui deline E6 (2016) and any
updates, and applicable regulations, before starting any study-related procedures.
4. Subject satisfies the following ADHD criteria during the scre ening period:
Meets the Diagnostic and Statistical Manual of Mental Disorders,  Fifth Edition (DSM-5)
criteria for a primary diagnosis of ADHD (any subtype) based on a detailed psychiatric
evaluation using the Mini International Neuropsychiatric Interv iew for Children and
Adolescents (MINI-KID)
Has an ADHD Rating Scale-5 (ADHD-RS-5) Child, Home Version Total Score of
≥28 for boys and ≥24 for girls
Has a Clinical Global Impressions-Severity of Illness (CGI-S) sco re ≥4.
5. Subject functions at an age-appropriate level intellectually, as determined by [CONTACT_093].
6. Subject has undergone an adequate course of nonpharmacologica l treatment ORthe subject
has a severe enough condition to consider enrollment without un dergoing prior
nonpharmacological treatment, based on the investigator’s judgm entORhas never taken
ADHD medication ORhas taken ADHD medication with unacceptable efficacy and/or
tolerability.
7. Subject has the ability to take investigational product by [CONTACT_38883].
8. Subject has lived with the same parent/LAR for at least 6 mont hs.
CONFIDENTIAL Page 29 Shire
Protocol SHP465-112 15 Sep 2017
4.2 Exclusion Criteria
Subjects are excluded from the study if any of the following ex clusion criteria are met:
1. Prior enrollment or participation in the study.
2. Subject has a documented alle rgy, hypersensitiv ity, or intoler ance to amphetamine or to any
excipi[INVESTIGATOR_38852].
3. Subject cannot swallow a pi[INVESTIGATOR_38847]/or applesauce, or has an al lergy to applesauce.
4. Subject is currently taking or has taken ADHD medication with acceptable efficacy and
tolerability.
5. Subject has taken ADHD medication within [ADDRESS_40636] has used any medication (including over-the-counter, herbal, or homeopathic
preparations) within [ADDRESS_40637] or
5 half-lives, whichever is longer, with the exception of the following:
Thyroid medication
Intermittent use of nonsteroidal anti-inflammatory drugs or ace taminophen for minor
aches and pains
As needed use of a beta-agonists inhaler for mild asthma or exer cise induced
bronchospasm
Over-the-counter nonsedating antihistamines such as fexofenadin e (ALLEGRA®, [COMPANY_011]),
loratadine ( CLARITIN®, Schering-Plough), or cetirizine hydrochloride ( ZYRTEC®,
McNeil-PPC) for allergies.
Subject has continuously used oral corticosteroids ≥[ADDRESS_40638] dosing. If continuous use was <[ADDRESS_40639]:
Subject has used an investigational product.
RIf the elimination half-life of the previous study's investigational product was less
than [ADDRESS_40640] dose of SHP465.
RIf the elimination half-life of the previous study's investigat ional product was greater
than [ADDRESS_40641] screening visit based on the investigator’s judgment. A  single retest of laboratory
parameters is allowed based on the investigator’s judgment.
12. Subject has Marfan’s syndrome.
13. Subject has a blood pressure ≥95th percentile for age, sex, and height at the screening visit
(Appendix 2.3 and Appendix 2.5 ).
14. Subject has a height 5th percentile for age and sex at the first screening visit ( Appendix 2.2
and Appendix 2.4).
15. Subject has a weight 5th percentile for age and sex at the first screening visit.
16. Subject has current abnormal thyroid function test results, d efined as abnormal
thyroid-stimulating hormone, thyroxine (T4), and tri-iodothyroni ne (T3) at the first screening
visit. Treatment with a stable dose of thyroid medication for a t least [ADDRESS_40642] has a history of seizures (other than infantile febr ile seizures).
18. Subject has a current, controlled (requiring medication or t herapy) or uncontrolled, comorbid
psychiatric disorder including but not limited to any of the fo llowing comorbid Axis I
disorders and Axis II disorders:
Post-traumatic stress disorder or adjustment disorder
Bipolar illness, psychosis/schizophrenia, or positive family hi story of these disorders in
first- or second-degree relatives
Pervasive developmental disorder
Obsessive-compulsive disorder
A serious tic disorder, or a family history of Tourette disorder
Substance abuse or dependence disorder
Any other disorder that, in the opi[INVESTIGATOR_871], cont raindicates SHP465 or
amphetamine treatment or confounds efficacy or safety assessmen ts.
19. Subject is currently considered a suicide risk in the opi[INVESTIGATOR_871], has
previously made a suicide attempt, or has a prior history of or  is currently demonstrating
active suicidal ideation.
20. Subject has a history of physical, s exual, or emotional abus e.
21. Subject has a primary sleep disorder (eg, sleep apnea, narco lepsy).
22. Subject has a history or is currently diagnosed with an eati ng disorder.
CONFIDENTIAL Page [ADDRESS_40643] has a clinically important abnormality on the urine drug and alcohol screen
(excluding the subject's current ADHD stimulant, if applicable)  at the first screening visit.
24. Subject lives with anyone who currently abuses stimulants or  cocaine, based on the
investigator’s judgment.
25. Subject has a concurrent chronic or acute illness (such as severe allergic rhinitis or an
infectious process requiring antibiotics), disability, or other condition that might confound
the results of safety assessments conducted in the study or tha t might increase risk to the
subject.
26. Subject has any additional condition(s) such as any signific ant illness or unstable medical
condition that, in the investigator's opi[INVESTIGATOR_1649], would prohibit the subject from completing the
study and /or could lead to difficulty complying with the proto col.
4.[ADDRESS_40644] may withdraw from the study, or the parent/LAR may wit hdraw the subject from the 
study, at any time for any reason without prejudice to their fut ure medical care by [CONTACT_38884]. The investigator or sponsor may withdraw  the subject at any time (eg, in the 
interest of subject safety). The investigator is encouraged to discuss withdrawal of a subject from 
investigational product with the medical monitor when possible.
If investigational product is discontinued, regardless of the reason, the early withdrawal 
evaluations listed in Table 1 and Table 2 are to be performed as completely as possible. 
Whenever possible, all discontinued subjects should also underg o the protocol-specified 
follow-up. Comments (spontaneous or elicited) or complaints mad e by [CONTACT_38885]. The reason for termination, d ate of stoppi[INVESTIGATOR_38853], and the total amount of investigational product taken m ust also be recorded in the 
source document.
Subjects who discontinue may be replaced at the discretion of t he investigator and sponsor to 
ensure at least 10 completers in each of the PK sampling portio ns of the study (of which at least 
[ADDRESS_40645] 3 subjects in the rich PK sample subset 
should be female).
4.4.[ADDRESS_40646] be further 
evaluated if they meet any of the criteria defined in Sections [IP_ADDRESS] and [IP_ADDRESS].
CONFIDENTIAL Page 32 Shire
Protocol SHP465-112 15 Sep 2017
[IP_ADDRESS] Systolic and Diastolic Blood Pressure
Blood pressure criteria for further evaluation have been developed based on the normative data 
presented in the National Institutes of Health Fourth Report on  the Diagnosis, Evaluation, and 
Treatment of High Blood Pressure in Children and Adolescents ( NIH, 2004 ).
Increases in blood pressure (both systolic and diastolic) from the 50th to the 95th percentile 
(representative of a change of [ADDRESS_40647] deviations) range from  17 mmHg to 20 mmHg for both 
boys and girls in this age range. Based on this range, an incre ase of >15 mmHg from the baseline 
visit (predose on Day 1) was selected for this protocol. 
If there are elevations in the average systolic and/or diastolic blood pressure based on the 
following defined criteria, further assessment will be required (average is of 3 readings with 
approximately 2 minutes between readings):
Elevations in average (of 3 readings) sitting systolic blood pres sure defined as an increase of
>15 mmHg from the baseline visit (predose on Day 1) or an avera ge (of 3 readings) sitting
systolic blood pressure value ≥95th percentile for age, sex, and height percentile.
Elevations in average (of 3 readings) sitting diastolic blood p ressure defined as an increase of
>15 mmHg from the baseline visit (predose on Day 1) or an avera ge (of 3 readings) sitting
diastolic blood pressure value ≥95th percentile for age, sex, a nd height percentile.
The investigator will discuss each subject who meets any criteri on with the medical monitor, and 
a joint decision between the investigator and the medical monit or will be made regarding 
continued participation in the study.
If the subject is allowed to remain in the study, an unschedule d visit will be conducted the next 
business day. If a visit cannot be conducted the next business day, the subject may be 
discontinued from the study.At the unscheduled visit, [ADDRESS_40648] with a systolic or diastolic blood pressure value <95th percentile for age, sex, and 
height percentile may be discontinued from the study based upon  the clinical judgment of the 
investigator regarding the subject’s safety.
[IP_ADDRESS] Pulse
The resting pulse rate criterion for further evaluation has been defined based on the normative 
data presented in the National Health Statistics Report’s “Rest ing Pulse Rate Reference Data for 
Children, Adolescents, and Adults: [LOCATION_002], 1999-2008” ( Ostchega et al., 2011). 
An elevation in the average (of 3 readings) sitting pulse, defi ned as >[ADDRESS_40649] may be 
discontinued from the study. At the unscheduled visit, the investigator will notify the medi cal monitor of the results, and if the 
pulse is still >[ADDRESS_40650] with a pulse rate ≥[ADDRESS_40651]’s safety.
4.4.[ADDRESS_40652]’s 
medical record and on the case report form (CRF). If a subject is withdrawn for more than 
[ADDRESS_40653] clinically 
relevant reason should be entered on the CRF.
Reasons for discontinuation include but are not limited to:
Adverse event (AE)
Protocol violation
Withdrawal by [CONTACT_31384]/LAR
Lost to follow-up
Blood pressure and/or pulse criteria for discontinuation met
Other (must be specified)
4.4.3 Subjects “Lost to Follow-up” Prior to Last Scheduled Visit
A minimum of [ADDRESS_40654] or parent/LAR in the 
event that any subject is lost to follow-up at any time point pr ior to the last scheduled contact 
(office visit or telephone contact). At least [ADDRESS_40655]’s last known address via courier or mail (with an 
acknowledgement of receipt request) asking that they return to the site for final safety 
evaluations and return any unused investigational product.
5 PRIOR AND CONCOMITANT TREATMENT
All nonstudy treatment (including but not limited to herbal tre atments, vitamins, and 
nonpharmacological treatment such as behavioral treatment) rece ived within 30 days prior to the 
screening visit (Day -1) (or PK equivalent of 5 half-lives, whi chever is longer) and through the 
final study contact (including the protocol-defined follow-up p eriod) must be recorded in the 
source document.
CONFIDENTIAL Page 34 Shire
Protocol SHP465-112 15 Sep 2017
5.1 Prior Treatment
Prior treatment includes all treatment (including but not limit ed to herbal treatments, vitamins, 
nonpharmacological treatment, such as behavioral treatment) rec eived within 30 days (or PK 
equivalent of 5 half-lives, whichever is longer) of the date of  the administration of 
investigational product. Prior treatment information must be re corded in the source document.
5.[ADDRESS_40656] be recorded in the source document.
5.2.1 Permitted Treatment
Subjects should refrain from taking any medications (excluding those medications that are 
permitted) during the course of the study. Any medication which is considered necessary for the subject’s safety and well-being may be given at the discretion of the investigator. The administration of all medications (including investigational products) must be listed in the source 
documents.
Medications permitted during the study are listed as follows:
Stable (ie, for at least 3 months prior to the screening visit) dose of thyroid medication
Stable (ie, for at least 1 month prior to the screening visit) d ose of bronchodilator inhalers
(however, oral beta-agonists and oral corticosteroids are prohib ited)
Any medications that do not affect blood pressure, heart rate, or the central nervous system,
and which are considered necessary for the subject's welfare, m ay be administered at the
discretion of the investigator
Nonsedating antihistamines such as fexofenadine (eg, 
ALLEGRA , [COMPANY_011]), loratadine
(eg, CLARITIN , Schering-Plough), and cetirizine hydrochloride (eg, ZYRTEC , McNeil PPC)
Over-the-counter nonstimulant cold remedies
A topi[INVESTIGATOR_38854].
5.2.2 Prohibited Treatment
Table 3 details the washout period for common prior treatments that are excluded medications 
for this study.
CONFIDENTIAL Page 35 Shire
Protocol SHP465-112 15 Sep 2017
Table 3: Common Excluded Treatments and Associated Washout Period Relative to 
Baseline Visit
Minimum Number of Days 
Before Baseline Visit
Treatment 7 14 30
Psychostimulants, amphetamines, and amphetamine-like agents X
AntihypertensivesaX
Methylxanthines (theophylline and aminophylline) X
Antihistamines (centrally and peripherally active) X
Herbal preparations (including melatonin) X
Sedatives, anxiolytics, antipsychoticsaX
Monoamine oxidase inhibitors (MAOIs)aX
AntidepressantsaX
Clonidine and guanfacine X
Selective noradrenaline reuptake inhibitors and noradrenaline reuptake inhibitorsaX
Cytochrome P450 2D6 inhibitors (eg, paroxetine, fluoxetine, qui nidine, ritonavir) X
Alkalinizing agents (eg, sodium bicarbonate, acetazolamide, some thiazides) X
Acidifying agents (eg, guanethidine, reserpi[INVESTIGATOR_050], glutamic acid h ydrochloride, 
ascorbic acid, ammonium chloride, sodium acid phosphate, methenamine salts)X
aThese medications may signal that an exclusionary diagnosis is present. The medical monitor should be consulted prior to instructing a subject to discontinue one of these medications f or this study. Baseline visit is considered as predose on Day 1.
[ADDRESS_40657] was 
previously referred to as SPD465 and is registered with the Dru g Enforcement Agency as 
SPD465; however, it is now being studied under the code of SHP4 65. The drug will be labeled 
with SHP465 (SPD465). Additional information is provided in the current SHP465 IB.
6.1.[ADDRESS_40658] numbers are assigned to all subjects as they consent/as sent to take part in the study. 
Within each site (numbered uniquely within a protocol), the sub ject number is assigned to 
subjects according to the sequence of presentation for study participation. This will be a 4-digit 
number starting at 0001.
A 4-digit subject number, starting at 1001, will be allocated i mmediately prior to dosing after 
eligibility has been determined. If a subject number is allocat ed incorrectly, the study monitor 
must be notified as soon as the error is discovered. Once a subject number has been assigned, 
that number must not be used again if, for example, a subject i s withdrawn from the study. For 
enrolled subjects, the subject number will be the identifying n umber used throughout the CRF.
If a unique identifier is allocated incorrectly, the clinical r esearch associate (CRA)/study monitor 
must be notified as soon as the error is discovered.
Investigational product packaging identification numbers, separ ate from unique identifiers, may 
also be assigned to subjects for specific treatment assignment as dictated by [CONTACT_1758]. In these 
cases, the same investigational product packing identification number may not be assigned to 
more than [ADDRESS_40659].
6.2.2 Dosing
There will be one SHP465 dose level of 6.25 mg used in this stud y. 
On Day 1 of each week (Weeks 1-4), all subjects will report to the CRC approximately 2 hours 
prior to the time of dosing for predose evaluations. The dose will be administered daily as a 
single dose for 28 days (±1 day) at 8:00 AM(±1 hour). Doses on Day 1 of each week 
(Weeks 1-4) will be administered in the CRC. The parent/LAR will  be dispensed a bottle 
containing the remaining doses for that week. The same parent/L AR should be available daily to 
dispense the dose of investigational product for the study durat ion.
For all subjects, investigational product will be taken by [CONTACT_38886] 1 tablespoon of applesauce. The sprinkled applesauce should be consumed immediately; it should not be stored. Subjec ts should take the applesauce 
with sprinkled beads in its entirety without chewing. A single capsule cannot be split. The empty 
gelatinous capsule should be discarded. 
On Day [ADDRESS_40660](s) container.
All investigational product is labeled with a minimum of the fol lowing:
protocol number
medication identification number (if applicable)
dosage form (including product name [CONTACT_38933])
directions for use, storage conditions, expi[INVESTIGATOR_5695] (if applica ble)
batch number and/or packaging reference
the statements “For clinical trial use only” and/or “CAUTION: N ew Drug – Limited by
[CONTACT_4496] (or US) Law to Investigational Use,” and “Keep out of reach of children,”
sponsor's name [CONTACT_38934] s and/or controlled substances will 
also be included on the label.Space is allocated on the label so that the site representative can record a unique subject 
identifier and initials.
Additional labels (eg, those used when dispensing marketed produ ct) may, on a case-by-case 
basis, be applied to the investigational product in order to sa tisfy local or institutional 
requirements, but must not:
Contradict the clinical study label
Obscure the clinical study label
Identify the study subject by [CONTACT_38887]’s prior full agreement.
6.3.[ADDRESS_40661] is packaged in the following labeled co ntainers:
SHP465 capsules are packaged in 9-count high density polyethylene bottles with child resistant 
closures.
CONFIDENTIAL Page [ADDRESS_40662]/nominated 
team member will enter the unique subject identifier and initials on the investigational product 
bottle/carton labels as they are distributed.
Investigational product must be stored in accordance with labeled storage conditions. 
Temperature monitoring is required at the storage location to ensure that the investigational product is maintained within an established temperature range. The investigator is responsible 
for ensuring that the temperature is monitored throughout the d uration of the study and that 
records are maintained; the temperature should be monitored continuously by [CONTACT_3570]-house system, a mechanical recording device such as a calibrated chart recorder, or by [CONTACT_10179], such that both minimum and maximum thermometric values ov er a specific time period 
can be recorded and retrieved as required. Such a device (ie, certified minimum/maximumthermometer) would require manual resetting upon each recording . The sponsor must be notified 
immediately upon discove ry of any excursion from  the establishe d range. Temperature 
excursions will require site investigation as to cause and reme diation. The sponsor will determine 
the ultimate impact of excursions on the investigational product and will provide supportive documentation as necessary. Under no circumstances should the p roduct be dispensed to subjects 
until the impact has been determined and the product is deemed appropriate for use by [CONTACT_103].
The sponsor should be notified immediately if there are any cha nges to the storage area of the 
investigational product that could affect the integrity of the product(s), eg, fumigation of a 
storage room.All controlled-substance investigational product for the sponsor’s studies must be stored in a 
securely locked, s ubstantially c onstructed room or cabinet according to all applicable local, state, 
and/or national laws. Limited, controlled access to these inves tigational products must be 
maintained, as well as chain of custody, for all investigationa l product movement.
6.[ADDRESS_40663] disp ensed, used, returned, and/or 
destroyed must be maintained as detailed further in this sectio n.
CONFIDENTIAL Page 39 Shire
Protocol SHP465-112 15 Sep 2017
The investigator has overall responsibility for administering/d ispensing investigational product. 
Where permissible, tasks may be delegated to a qualified design ee (eg, a pharmacist) who is 
adequately trained in the protocol and who works under the dire ct supervision of the investigator. 
This delegation must be documented in the applicable study dele gation of authority form.
The investigator or his/her designee (as documented by [CONTACT_38888]) will administer the investigationa l product only to subjects 
included in this study following the procedures set out in the study protocol. Each subject will be 
given only the investigational product carrying his/her treatme nt assignment. All administered 
medication will be documented in the source documents and/or othe r investigational product 
record.
No investigational product stock or returned inventory from a S hire-sponsored study may be 
removed from the site where originally shipped without prior kn owledge and consent by [CONTACT_103]. If such transfer is authorized by [CONTACT_456], all app licable local, state, and national 
laws must be adhered to for the transfer.
The sponsor or its representatives must be permitted access to review the supplies storage and 
distribution procedures and records.
At the end of the study, or as instructed by [CONTACT_456], all unused stock and empty/used 
investigational product packaging are to be sent to a nominated contractor on behalf of the sponsor. Investigational products being returned to the sponsor’s designated contractors must be counted and verified by [CONTACT_38889] (or designated contract research 
organization [CRO]). For unused supplies where the original supplied tamper-evident feature is verified as intact, the tamper-evident feature must not be brok en, and the labeled amount is to be 
documented in lieu of counting. Shipment return forms, when used, must be signed prior to shipment from the site. Validated electronic return systems (ie , interactive response technology) 
do not require a shipment form. Returned investigational produc ts must be packed in a 
tamper-evident manner to ensure product integrity. Contact [CONTACT_38890]. Shipment of all returned investigational 
product must comply with local, state, and national laws.
Based on entries in the site drug accountability forms, it must  be possible to reconcile 
investigational products delivered with those used and returned . All investigational products 
must be accounted for and all discrepancies investigated and do cumented to the sponsor’s 
satisfaction.
6.[ADDRESS_40664] has been ingested. The 
investigator/nominated person will record details on the drug a ccountability form(s) and/or 
source documents. In addition, details of the dosing time (time , date, dose level) will be captured.
CONFIDENTIAL Page 40 Shire
Protocol SHP465-112 15 Sep 2017
The parent/LAR will also be provided with a diary with customiz ed questions to record the times 
when the investigational product was given to the child.
The parent/LAR of each subject must be instructed to bring thei r unused investigational product 
and empty/used investigational product packaging to every visit . Drug accountability must be 
assessed at the container/packaging level for unused investigat ional product that is contained 
within the original tamper-evident sealed container (eg, bottle s, trays, vials) or at the individual 
count level for opened containers/packaging. The pharmacist/nominated person will record 
details on the drug accountability form.
Subjects who have taken 80% to 100% of the investigational prod uct are regarded as being 
compliant with the study protocol. Compliance must be assessed by [CONTACT_093].
The calculation of medication compliance is as follows:For whole capsules:
Protocolby [CONTACT_38891]100 Taken Capsules TotalCompliance
For capsule contents sprinkled in applesauce:
Protocolby [CONTACT_38891]100 Taken Doses Sprinkled TotalCompliance
To ensure that the maximum amount of capsule contents has been taken when sprinkled onto 
applesauce, the total amount of applesauce used is limited to [ADDRESS_40665] to the site.
7 STUDY PROCEDURES7.1 Study Schedule
The Schedule of Assessments ( Table 1 for the rich PK sample subset and Table 2 for the sparse 
PK sample subset) details all procedures to be completed at each visit and should serve as the 
primary section of the protocol regarding visit-specific study procedures.
The following “priority order” will be in effect at the screeni ng visit:
Medical and medication history and physical examination
Vital signs and ECG
PK blood sampling
Clinical laboratory tests
CONFIDENTIAL Page 41 Shire
Protocol SHP465-112 15 Sep 2017
Clinician-completed rating scales and assessments conducted by [CONTACT_779], ie, ADHD-RS-5,
Child, Home Version; CGI-S; MINI-KID; Post Sleep Questionnaire (PSQ ); and the
Columbia-Suicide Severity Rating Scale (C-SSRS) must be complet ed by [CONTACT_38892].
At all other visits, which require more than one procedure or assessment, the following priority 
order will be in effect:
Spontaneous or solicited AE reporting
Vital signs and ECG
PK blood sampling
Clinical laboratory tests
Physical examination
Additional unscheduled visits and/or assessments may occur as n eeded for safety 
(eg, unscheduled visits for blood pressure and/or pulse measurements will be conducted as 
described in Section 4.4.1 ).
NOTE: Blood sampling for PK evaluation must be performed at the p recise protocol-scheduled 
time. Actual sampling time(s) must be accurately recorded in th e source document.
7.1.[ADDRESS_40666] of screening procedures to be performe d is provided in Table 1 for the 
rich PK sample subset and Table 2 for the sparse PK sample subset.
The principal investigator [INVESTIGATOR_022]/her designee must obtain writ ten informed consent and assent
from the subject’s parent/LAR prior to any study-related proced ures conducted during the 
screening period. There must also be documentation of assent (i f required by [CONTACT_38893] [IRB]), indicating that the subject is aware of the  investigational nature of the study 
and the required procedures and restrictions, prior to the perf ormance of any study-related 
procedures.
If subjects are currently taking ADHD medication, they are to d iscontinue their current ADHD 
medication at least [ADDRESS_40667] (please refer to
Section 4.2for additional information).
Screening procedures may take place across multiple days to all ow enough time to complete all 
procedures and confirm initial subject eligibility. Screening p rocedures and dates should be well 
documented in the source documents. The date of the screening v isit is the date the parent/LAR 
has signed informed consent for this study.
CONFIDENTIAL Page [ADDRESS_40668] who has given informed consent an d failed to meet any of the 
inclusion and/or met at least [ADDRESS_40669](s).
Subjects cannot be rescreened once they have been designated as  a definite screen failure. 
Reassessment of subjects who failed specific inclusion/exclusion criteria is not allowed.
7.1.[ADDRESS_40670] of 1 treatment period:
The subject will receive a single 6.25-mg dose of SHP465 once d aily for 28 days (±1 day) at
8:00 AM(±1 hour)
The assessments and procedures performed during the study are o utlined in Table 1 (rich PK 
sample subset) and Table 2 (sparse PK sample subset).
Rich PK Sample Collection Subset
Predose PK samples will be collected on Day 1 of Week 1, and se rial blood samples for PK 
analysis will be drawn prior to dosing on Day 7 of Week 4 (within 60 minutes prior to dosing) 
and up to [ADDRESS_40671].
On Day 7 of Week 4, subset of subjects in the rich PK sampling portion will be required to 
remain at the CRC through 8 hours postdose. Following completio n of the 8-hour PK sample 
collection, per investigator’s discretion, subjects will have the option to remain at or leave the CRC. If they leave the CRC, subjects will either return to the CRC on Days 7, 8, and [ADDRESS_40672] clin ic visit: on Day 9 of Week 4 
(approximately [ADDRESS_40673]) for subjects in the rich PK 
sampling portion and on Day 8 of Week 4 (approximately [ADDRESS_40674]) for subjects in the sparse PK sampling  portion of the study.
7.1.[ADDRESS_40675] clinic visit, subjects and their parent/LAR will be  offered to rollover into the 
SHP465-308 study. If subjects agree and their parent/LAR signs t he informed consent form, this 
will end their participation in the SHP465-[ADDRESS_40676] will be conducted. 
CONFIDENTIAL Page 43 Shire
Protocol SHP465-112 15 Sep 2017
For those subjects with ongoing AEs, a mandatory in-person follow-up vi sit at the CRC will 
occur 7 days (±2 days) following the subject’s last dose of investigational product to collect 
information on any ongoing or new AEs, serious AEs (SAEs), or concomitant medications, as appropriate.
At the investigator’s discretion, for those subjects with no ongoing AEs at the time of the last 
scheduled assessment, a telephone call initiated by [CONTACT_38894]-person follow-up visit at 
the CRC will occur 7 days (±2 days) following the subject’s dose of investigational product to 
collect information on any new AEs, SAEs, or concomitant medications, as appropriate. All AEs and SAEs that are not resolved at the time of this contact [CONTACT_38895] (Section 8.1).
7.1.[ADDRESS_40677] completed the study at Day 9 of Week 4 (rich PK sample subset) or at Day 8 
of Week 4 (sparse PK sample subset) may be evaluated for eligibility to enter a long-term safety 
study of SHP465.
7.2 Study Evaluations and Procedures
7.2.1 Demographic and Other Baseline Characteristics
Demographic characteristics such as age, gender, weight, and he ight will be collected according 
to Table 1 (rich PK sample subset) and Table 2 (sparse PK sample subset).
Clinician-completed rating scales and assessments conducted by t he site, ie, ADHD-RS-5 
Child, Home Version; MINI-KID; CGI-S; and C-SSRS must be completed by [CONTACT_38896]. The parent/LAR-completed Children’s Sleep Habits Questionnaire (CSHQ) and the PSQ must be completed by [CONTACT_38897].
[IP_ADDRESS] Mini International Neuropsychiatric Interview for Children and 
Adolescents (MINI-KID)
The MINI-KID is a structured clinical diagnostic interview desi gned to assess the presence 
of psychiatric disorders in children and adolescents in a way th at is comprehensive and 
concise. It follows the structure and format of the adult version of the interview and is 
organized in diagnostic sections or modules. Using branching tre e logic, the instrument asks 
[ADDRESS_40678] common and clinically relevant disorde rs or disorder subtypes in 
pediatric mental health. With this version, the child and parent are interviewed together. Additional symptom questions within each disorder section are a sked only if the screen 
questions are positively endorsed. The MINI-KID is the structure d psychiatric interview of 
choice for psychiatric evaluation and outcome tracking in clini cal psychopharmacology trials 
and epi[INVESTIGATOR_9037]. In a validation study ( Sheehan et al., 2010 ), the MINI-KID 
generated reliable and valid psychiatric diagnoses for children  and adolescents and does so in 
one-third of the time as the Kiddie Schedule for Affective Diso rders and Schizophrenia 
Present and Lifetime Version. 
CONFIDENTIAL Page 44 Shire
Protocol SHP465-112 15 Sep 2017
The MINI-KID should be completed by [CONTACT_38898], and may include phy sicians, or licensed 
psychologists/clinicians. All individuals performing this assessment must be preapproved by [CONTACT_36613]. 
[IP_ADDRESS] Clinical Global Impressions
The Clinical Global Impressions Scale which measures severity o f illness (CGI-S) will be 
performed at the time points described in Table 1 . The CGI-S ( Guy, 1976 ) permits a global 
evaluation of the subject’s severity and improvement over time.  The CGI-S has been used 
extensively in clinical studies of ADHD ( Michelson et al., 2001; Weiss et al., 2005; Wilens et al., 
2001).
The investigator will perform the CGI-S to rate the severity of  a subject’s condition on a 7-point 
scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill subjects) at the 
baseline visit.
The CGI-S will be completed by a clinician trained and experienc ed in the evaluation of 
preschool children with ADHD.The title, version, and date of the CGI-S used in this study ar e included in Appendix 3 .
[IP_ADDRESS] The ADHD-Rating Scale-5
The ADHD-RS-5 Child, Home Version ( DuPaul et al., 2016 ) is completed by t he clinician and 
will be administered at baseline. 
The ADHD-Rating Scale was developed to measure the behaviors of  children with ADHD and is 
commonly used in clinical studies of ADHD ( Buitelaar et al., 2007 ; Döpfner et al., 2006; 
Kratochvil et al., 2001; Michelson et al., 2001; Spencer et al., 2001 ). The ADHD-RS-[ADDRESS_40679] current symptomatology of ADHD based on DSM-5 criteria. 
Each item is scored on a 4-point scale ranging from 0 (reflecting no symptoms) to 3 (reflecting 
severe symptoms) with total scores ranging from 0 to 54. The 18 items may be grouped into 2 subscales: hyperactivity/impulsivity (9 items) and inattentive ness (9 items).
The ADHD-RS-[ADDRESS_40680]-party vendor (eg, clinical laboratory) used in this study will 
be maintained in the investigator’s and sponsor’s files.
CONFIDENTIAL Page 45 Shire
Protocol SHP465-112 15 Sep 2017
Actual safety assessment times will be monitored and recorded. The sponsor’s expectation is that 
the investigator will ensure that every effort is made to perfo rm all assessments at the precise 
protocol-scheduled time. Any safety assessment that deviates fr om the scheduled assessment 
time set forth in the protocol by [CONTACT_726] 30 minutes will be considered a protocol deviation.
[IP_ADDRESS] Medical and Medication History
A complete medical and medication history, as well as demograph ic information, will be 
performed at the screening visit/time points described in Table 1 (rich PK sample subset) and 
Table 2 (sparse PK sample subset) by a qualified licensed physician, ph ysician’s assistant, or a 
nurse practitioner. The medical history will be reviewed and recorded, including:
Date of birth
Sex
Race and ethnicity
Recent ingestion of medication (30 days prior to entering the screening period)
History of respi[INVESTIGATOR_696], cardiovascular, renal, gastrointestinal , hepatic, endocrine,
hematological, neurological, psychiatric, and other diseases
With the consent of the subject’s parent/LAR, medical records f rom other treatment providers 
should be requested.
[IP_ADDRESS] Physical Examination (Including Height and Weight)
A complete physical examination will be performed at the time p oints described in Table 1 (rich 
PK sample subset) and Table 2 (sparse PK sample subset) by a qualified licensed physician, 
physician’s assistant, or nurse practitioner.
The physical examination will include a review of the following  body systems:
General appearance
Skin
Head, eyes, ears, nose, and throat
Spi[INVESTIGATOR_050]/neck/thyroid
Musculoskeletal
Respi[INVESTIGATOR_696]
Cardiovascular
Neurological
Abdomen (including liver and kidneys)
CONFIDENTIAL Page 46 Shire
Protocol SHP465-112 15 Sep 2017
Abnormalities identified at the screening visit will be documented in the source documents. 
Changes after the screening visit will be captured as AEs as dee med appropriate by [CONTACT_1275].
Height and weight will be measured at the time points described i n Table 1 (rich PK sample 
subset) and Table 2 (sparse PK sample subset). 
A calibrated stadiometer must be used for all height measuremen ts. Height should be measured 
in centimeters or inches without shoes with the subject standing on a flat surface and with the 
chin parallel to the floor. The body should be straight but not rigid. The subject’s height should be recorded as accurately as possible and should be recorded to  the nearest centimeter or nearest 
inch.
The same calibrated scale must be used for all weight measurements. Weight should be 
measured in kilograms or pounds without shoes and with light clothing and recorded as accurately as possible and should be recorded to the nearest 0. [ADDRESS_40681] 0.1 lb. Weight and 
height measuring apparatus should be calibrated/tested prior to  study initiation.
[IP_ADDRESS] Adverse Event Collection
At each study visit, subjects will be questioned in a general w ay to ascertain whether AEs have 
occurred since the previous visit (eg, “Have you had any health problems since your last visit?”). 
This information should be collected before the completion of as sessments at all study visits. In 
addition, any symptoms and signs/conditions reported during asse ssments and deemed to be 
clinically significant by [CONTACT_38899]. Adverse events are collected 
from the time informed consent is signed. (Please refer to Sect ion8, Adverse and Serious 
Adverse Events Assessment.)
[IP_ADDRESS] Vital Signs
Vital signs, including systolic and diastolic blood pressure, p ulse rate, respi[INVESTIGATOR_857], and body 
temperature, will be measured at the times specified in Table 1 (rich PK sample subset) and
Table 2 (sparse PK sample subset). Subjects should be resting in a sitt ing position for at least 
5 minutes prior to collecting vital signs, legs should be uncros sed, and the back and arm should 
be supported. Measurements of sitting systolic and diastolic blo od pressure and pulse will be 
performed 3 times at each time point, with approximately 2 minute s between each measurement; 
both individual measurements and the averaged reading should be recorded in the source 
document.
Blood pressure will be determined by [CONTACT_38900]-appropriate cuff (the same equipment and 
the same arm should be used throughout the study). A blood pres sure cuff appropriate for the 
subject’s arm length and girth should be used for all blood pressure measurements. The cuff should be approximately two-thirds the length/width of the subje ct’s arm (from elbow to 
shoulder). All blood pressure measurements should be performed by [CONTACT_38901] (if possible) throughout the study.
Pulse rate should be counted for [ADDRESS_40682] (ie, pretending he/she is taking the subject’s radial pulse) 
and count the respi[INVESTIGATOR_38855] 1 minute. 
Body Temperature
An electronic/chemical dot thermometer in the axilla or an infr ared tympanic thermometer 
should be used for measuring the temperature. The thermometer s hould be left in position for 
sufficient time to gain an accurate reading, according to the manufacturer’s instructions. The 
same method of obtaining temperature should be used throughout the study in a given subject.
[IP_ADDRESS] Clinical Laboratory Evaluations
All clinical laboratory assays will be performed according to t he laboratory’s normal procedures. 
Reference ranges are to be supplied by [CONTACT_38902]-of-range patho logical changes. The investigator 
should assess out-of-range clinical laboratory values for clini cal significance, indicating if the 
value(s) is/are not clinically significant or is/are clinically  significant. Abnormal clinical 
laboratory values, which are unexpected or not explained by [CONTACT_19578]’s clinical condition, 
may, at the discretion of the investigator or sponsor, be repeated as soon as possible until 
confirmed, explained, or resolved.
Clinical laboratory assessments will be performed at the time po ints indicated in Table 1 (rich 
PK sample subset) and Table 2 (sparse PK sample subset) and include the following:
Biochemistry
Blood samples (2 mL) for serum biochemistry will be collected in to a serum separator tube at the 
time points described in Table 1 (rich PK sample subset) and Table 2 (sparse PK sample subset) . 
The following parameters will be assessed:
Sodium Total protein
Potassium Total CO 2(bicarbonate)
Glucose Albumin
Blood urea nitrogen Aspartate transaminase Creatinine Alanine transaminase Calcium Gamma glutamyl transferase Chloride Alkaline phosphatase Thyroid-stimulating hormone Total bilirubin Thyroxine (T4 total) Uric acidTri-iodothyronine (T3)Phosphorus
CONFIDENTIAL Page 48 Shire
Protocol SHP465-112 15 Sep 2017
Hematology
Blood samples (1 mL) for hematology will be collected into a K 2EDTA plastic tube at the time 
points described in Table 1 (rich PK sample subset) and Table 2 (sparse PK sample subset). The 
following parameters will be assessed:
Hemoglobin Total neutrophils (absolute and relative)
Hematocrit Eosinophils (absolute and relative)
Red blood cells Monocytes (absolute and relative)Platelet count Basophils (absolute and relative)White blood cell count; total and differentialpercentageLymphocytes (absolute and relative)
Urinalysis
A urine sample for urinalysis will be collected at the time poi nts described in Table 1 (rich PK 
sample subset) and Table 2 (sparse PK sample subset) . The following parameters will be 
assessed:
pH Blood Nitrites
Glucose Ketones Leukocyte esterase
Protein Bilirubin Specific gravity
Microscopic examination will be conducted if protein and/or blood is/are detected during 
urinalysis. At a minimum the microscopic examination will consi st of red blood cells, white 
blood cells, casts, and bacteria. 
[IP_ADDRESS] Drug and Alcohol Screen
A urine screen for drugs of abuse and alcohol will be performed at the time point shown in 
Table 1 (rich PK sample subset) and Table 2 (sparse PK sample subset). Additional drug and 
alcohol screens may be performed at the investigator’s discreti on.
Urine samples are to be tested for amphetamines, barbiturates, benzodiazepi[INVESTIGATOR_1651], cannabinoids, cocaine, methadone, opi[INVESTIGATOR_10149], and phencyclidine.
Results of urine drug and alcohol screens will be reviewed and verified by [CONTACT_11200], but 
will not be collected in the CRF database.Any positive result for drugs of abuse or alcohol at the first screening visit (with the exception of 
the subject’s current stimulant therapy) will exclude the subje ct from further participation in the 
study.
[IP_ADDRESS] Electrocardiogram
Twelve-lead ECGs will be performed at the times specified in Table 1 (rich PK sample subset) 
and Table 2 (sparse PK sample subset). All ECGs will be performed after [ADDRESS_40683] using 
equipment approved by [CONTACT_38903] t to the central ECG provider 
according to the instructions in the ECG manual provided by [CONTACT_38904]. 
CONFIDENTIAL Page 49 Shire
Protocol SHP465-112 15 Sep 2017
Additionally, ECGs will be performed in triplicate (with a 2 to 5 minute gap between traces) at 
screening. The subject should be asked to remove all clothing t hat covers the locations of lead 
placement. The subject must be resting in the supi[INVESTIGATOR_21683] [ADDRESS_40684] ed on the CRF. A trace ECG 
recording will be printed and placed in the site’s study file f or every ECG taken.
The initial interpretation of the ECG, normal or abnormal and cl inical significance, will be 
performed by [CONTACT_38905] e nsure the safety of each subject. 
An ECG tracing will then be evaluated by a pediatric cardiologist  at a central ECG reading 
vendor and returned to the site with a determination of normal or abnormal. Upon review of the 
report from this vendor, the investigator will re-evaluate the clinical significance of the ECG 
while taking into consideration all other safety data available  for the subject.
Although a central ECG reader is being used for this study, the eligibility of the subject is based 
on the investigator’s assessment of the ECG. If abnormal and significant results are observed following assessment by [CONTACT_9251], the investigator, i n consultation with the appointed 
CRO Medical Monitor, confirms subject eligibility to continue. Al l ECGs transmitted to the 
central ECG reader will be analyzed. If the central ECG reader receives multiple ECGs, the first 
readable ECGs will be analyzed as the scheduled ECG. Every ECG t ransmitted to the central 
ECG reader will have corresponding source document data collect ed. No ECG should be deleted 
by [CONTACT_26271]. All ECGs must be transmitted to the ce ntral provider regardless of 
quality, results, or number of ECGs tak en at a respective visit .
[IP_ADDRESS] Columbia-Suicide Severity Rating Scale
The C-SSRS ( Posner, 2007) is a semistructured interview that captures the occurrence, s everity, 
and frequency of suicide related thoughts and behaviors during t he assessment period. The 
interview includes definitions and suggested questions to solic it the type of information needed 
to determine if a suicide-related thought or behavior occurred.
The C-SSRS contains [ADDRESS_40685] be pre-approved by [CONTACT_38906].
CONFIDENTIAL Page 50 Shire
Protocol SHP465-112 15 Sep 2017
The Pediatric/Cognitively Impaired Version of the scale will be u sed in the study. Two 
time-point versions of the C-SSRS are used in this study as fol lows:
The “baseline” version will be administered at the screening vis it.
The “since last visit” version will be completed at all study v isits after the screening visit.
The title, version, and date of the C-SSRS “baseline” version a nd the C-SSRS “since last visit”
version used in this study are included in Appendix 3 .
[IP_ADDRESS] Children’s Sleep Habits Questionnaire
The CSHQ is a tool designed to screen for the most common sleep  problems in children and 
consists of 33 items for scoring and several extra items intend ed to provide administrators with 
other potentially useful information about respondents. The ins trument evaluates the child’s 
sleep based on behavior within 8 different subscales: bedtime r esistance, sleep-onset delay, sleep 
duration, sleep anxiety, night waking’s, parasomnias, sleep diso rdered breathing, and daytime 
sleepi[INVESTIGATOR_008]. The CSHQ will be conducted at each visit to the sit e starting with the baseline visit 
(predose on Day 1 of Week 1) and will be completed by [CONTACT_29320]’s parent/LAR.
[IP_ADDRESS] Post Sleep QuestionnaireThe PSQ is a 7-item questionnaire typi[INVESTIGATOR_38856]. The questionnaire collects data on average time to s leep, sleep latency, frequency of 
interrupted sleep, duration of interrupted sleep, total sleep t ime, and sleep quality over the last 
week. The PSQ will be completed by [CONTACT_7071]/LAR with the subject and the responses will be 
reviewed by [CONTACT_38907]. The PSQ will be completed and will be 
conducted at each visit to the site starting with the baseline visit (predose on Day 1 of Week 1). 
The title, version, and date of the PSQ version used in this st udy are included in Appendix 3 .
[IP_ADDRESS] Suitability of the Subject to Remain in the Study
At each visit (except for early termination) starting with the b aseline visit, the investigator will 
assess the subject’s ability to continue in the study. The inve stigator or a medically qualified 
designee will review all available safety information (includin g sleep behavior, w eight, and body 
mass index) and will evaluate for the presence of insomnia or d ecreased appetite potentially 
leading to weight loss. In cases where the subject has clinical ly significant decrease in appetite or 
insomnia, the investigator should intervene as necessary based on clinical judgment (eg, diet, 
behavioral interventions, sleep hygiene) and consider discontin uation of treatment if necessary. 
In any cases where a subject has clinically significant and per sistent sleep difficulties (eg, the 
CSHQ score of ≥41 for 2 consecutive weeks since the beginning of  treatment) or has had ≥7% 
weight loss, the investigator must discuss the case with the med ical monitor and assess whether 
it’s in the best interest for the subject to remain in the stud y. The evaluation and decision should 
also be clearly documented in the subject’s source notes.
As part of the assessment of the subject’s suitability to remai n in the study the investigator 
should also assess the subject’s current potential for suicide,  suicidal ideation, self-harm, or 
harm to others, as well as psychiatric disorders. The investigator should make this assessment by 
[CONTACT_14664] a clinical interview with the subject and by [CONTACT_38908], including results of the C-SSRS. 
CONFIDENTIAL Page [ADDRESS_40686] has suffered an accidental 
injury, the investigator should ensure that this was a true acc idental injury, rather than an epi[INVESTIGATOR_38857]-harming or a suicide attempt.
The investigator should pay particular attention to:
Any ‘yes’ response to Items 2, 3, 4, or [ADDRESS_40687]’s source notes should clearly document that the ass essment of continued suitability 
including assessment of the subject’s appetite, weight loss, insomnia and current potential risk of 
suicide, suicidal ideation, feelings of hopelessness, drug use, self-harm, or harm to others has taken place and should contain the decision on whether the subject is suitable to continue in the study.
7.2.3 Pharmacokinetic Procedures
The name [CONTACT_38935]’s files at each site and in the Trial Master File at the CRO.
Actual PK blood sample collection times versus time of dosing will be monitored. The sponsor’s expectation is that the investigator will ensure that every eff ort is made to collect all PK blood 
samples at the precise protocol-scheduled time. Pharmacokinetic  blood collection must not 
deviate from the nominal collection time set forth in the proto col by [CONTACT_726] 5 minutes from 
samples drawn within 4 hours postdose or by [CONTACT_726] 15 minutes for samples drawn beyond 
4 hours postdose. Samples drawn outside these parameters will be considered a protocol deviation. On Days 8 and 9 when subjects return to the CRC or for subjects who choose to remain in the CRC for the 24-hour and 48-hour postdose collection of PK samples, all efforts 
should be made to meet the 15 minute window; however, it will not be considered a protocol 
deviation unless the sample is collected more than ±60 minutes po stdose for those collection 
times.
[IP_ADDRESS] Blood Sample Collection and Handling Procedures
Blood samples will be collected at the time specified in Table 1 (rich PK sample subset) and 
Table 2 (sparse PK sample subset) to measure plasma concentrations of d-amphetamine and 
l-amphetamine. Potential metabolites may also be determined as appropriate.
Blood samples (2 mL) for PK analysis will be drawn by [CONTACT_38909]-dwelling catheters 
into appropriately labelled K
2EDTA Vacutainer®blood collection tubes (BD Vacutainer 
K2EDTA 2 mL tube, catalog number BD 367841, lavender top or equivalent) until the vacuum is 
exhausted and blood ceases to flow. Please refer to the Laborato ry Manual for additional details.
The actual time that the sample was obtained will be recorded i n the source document. In 
instances where more than [ADDRESS_40688] is provided i n Table 4 for the rich PK 
sample subset and Table 5 for the sparse PK sample subset.
Table 4: Volume of Blood to be Drawn from Each Subject (Rich Pharm acokinetic 
Sample Subset)
Assessment Sample Volume (mL)Number of 
SamplesTotal Volume (mL)
Pharmacokinetic samplesa2 or 3 9 18 - 27
Safety Biochemistry 2 2 4
Hematology 1 2 2
Total (mL) [ADDRESS_40689] mL is to be discarded; the next 2 mL are to be collected into the appropriate tube for the 
pharmacokinetic sample. A total of 3 mL of blood drawn has been used in determination of sample volume.
Table 5: Volume of Blood to be Drawn from Each Subject (Sparse Pha rmacokinetic 
Sample Subset)
Assessment Sample Volume (mL)Number of 
SamplesTotal Volume (mL)
Pharmacokinetic samples 2 4 8
Safety Biochemistry 2 2 4
Hematology 1 2 2
Total (mL) 14
During this study, it is expected that approximately 24 mL to 33 mL of blood will be drawn from 
subjects in the rich PK sample subset and 14 mL of blood will be  drawn from subjects in the 
sparse PK sample subset, regardless of sex. It is expected that  a maximum of approximately 
18 mL will be drawn in any 24-hour period; the 18 mL corresponds to Day 7 of Week 4, where 
there will be 6 PK draws from predose to 16 hours postdose × 3 mL  per draw if a catheter is 
used.
Note: The amount of blood to be drawn for each assessment is an estimate. The amount of blood 
to be drawn may vary according to the instructions provided by t he manufacturer or laboratory 
for an individual assessment; however, the total volume drawn over the course of the study should be approximately 24 mL to 33 mL of blood will be drawn fro m subjects in the rich PK 
sample subset and 14 mL of blood will be drawn from subjects in  the sparse PK sample subset. 
When more than 1 blood assessment is to be done at the time poi nt/period, if they require the 
same type of tube, the assessments may be combined.
CONFIDENTIAL Page [ADDRESS_40690] a cau sal relationship with this 
treatment. An AE can therefore be any symptom, unfavorable and unintended sign (including an 
abnormal laboratory finding), or disease temporally associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product (ICH Guideline E2A [1994]).
All AEs are collected from the time the informed consent form is signed until the defined 
follow-up period stated in Section 7.1.3. This includes events occurring during the screening 
phase of the study, regardless of whether or not investigationa l product is administered. Where 
possible, a diagnosis rather than a list of symptoms and signs should be recorded. If a diagnosis 
has not been made, then each symptom and sign should be listed individually. All AEs should be 
captured in the source documents. In addition to untoward AEs, unexpected benefits outside the investigational product indication should also be captured.
All AEs must be followed to closure (the subject’s health has returned to his/her baseline status 
or all variables have returned to normal), regardless of whether the subject is still participating in the study. Closure indicates that an outcome is reached, stabil ization achieved (the investigator 
does not expect any further improvement or worsening of the event), or the event is otherwise explained. When appropriate, medical tests and examinations are  performed so that resolution of 
event(s) can be documented.
8.1.[ADDRESS_40691] be recorded as new AEs (for example, if a subject experiences mild  intermittent dyspepsia prior to 
dosing of investigational product, but the dyspepsia becomes se vere and more frequent after the 
dose of investigational product has been administered, a new AE of severe dyspepsia [with the appropriate date of onset] is recorded in the source document).
The medical assessment of severity is determined by [INVESTIGATOR_1477]:
Mild : A type of AE that is usually transient and may require only mi nimal treatment or 
therapeutic intervention. The event does not generally interfer e with usual 
activities of daily living.
Moderate : A type of AE that is usually alleviated with specific therapeu tic intervention. The 
event interferes with usual activities of daily living, causing discomfort but poses 
no significant or permanent risk of harm to the research subjec t.
Severe : A type of AE that interrupts usual activities of daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervent ion.
CONFIDENTIAL Page 55 Shire
Protocol SHP465-112 15 Sep 2017
8.1.2 Relationship Categorization
A physician/investigator must make the assessment of relationsh ip to investigational product for 
each AE. The investigator should decide whether, in his or her medical judgment, there is a 
reasonable possibility that the event may have been caused by t he investigational product. If 
there is no valid reason for suggesting a relationship, then th e AE should be classified as “not 
related”. Otherwise, if there is any valid reason, even if unde termined or untested, for suspecting 
a possible cause-and-effect relationship between the investigat ional product and the occurrence 
of the AE, then the AE should be considered “related”. The caus ality assessment must be 
documented in the source document.
The following additional guidance may be helpful:
Term Relationship Definition
RelatedThe temporal relationship between the event and the administration of the 
investigational product is compelling and/or follows a known or suspected response 
pattern to that product, and the event cannot be explained by t he subject’s medical 
condition, other therapi[INVESTIGATOR_014], or accident.
Not RelatedThe event can be readily explained by [CONTACT_1605]’s underlying 
medical condition, concomitant therapy, or an accident, and no p lausible temporal or 
biologic relationship exists between the investigational product  and the event.
8.1.[ADDRESS_40692] udy in the source documents. 
Outcomes are as follows:
Fatal
Not Recovered/Not Resolved
Recovered/Resolved
Recovered/Resolved With Sequelae
Recovering/Resolving
Unknown
8.1.4 Symptoms of the Disease under Study
Symptoms of the disease under study should not be classed as AEs as long as they are within the 
normal day-to-day fluctuation or expected progression of the di sease and are part of the efficacy 
data to be collected in the study; however, significant worseni ng of the symptoms should be 
recorded as an AE.
8.1.[ADDRESS_40693] to the start of study 
treatment, further investigations should be performed until the values return to within the 
reference range or until a plausible explanation (eg, concomitan t disease) is found for the 
abnormal values.
The investigator should decide, based on the above criteria and the clinical condition of a 
subject, whether a change in a clinical laboratory, vital sign,  or ECG parameter is clinically 
significant and therefore represents an AE.
8.1.6 Abuse, Misuse, Overdose, and Medication Error
Abuse, misuse, overdose, or medication error (defined as follow s) must be reported to the 
sponsor according to the SAE reporting procedure whether or not they result in an AE/SAE as 
described in Section 8.2. Note: The 24-hour reporting requirement for SAEs does not app ly to 
reports of abuse, misuse, overdose, or medication errors unless these result in an SAE. 
The following categories are not mutually exclusive; the event can meet more than 1 category.
Abuse – Persistent or sporadic intentional intake of investigational p roduct when used for a
nonmedical purpose (eg, to alter one’s state of consciousness or  get high) in a manner that
may be detrimental to the individual and/or society
Misuse – Intentional use of investigational product other than as direc ted or indicated at any
dose (Note: this includes a situation where the investigational product is not used as directed
at the dose prescribed by [CONTACT_760])
Overdose – Intentional or unintentional intake of a dose of investigational product higher
than the protocol-prescribed dose
Medication Error – An error made in prescribing, dispensing, administration, and/or use of
an investigational product. For studies, medication errors are reportable to the sponsor onlyas defined as follows:
Cases of subjects missing doses of the investigational product are not considered
reportable as medication errors.
Medication errors should be collected/reported for all products under investigation.
The administration and/or use of an expi[INVESTIGATOR_38858] a reportable medication error.
All investigational product provided to pediatric subjects shou ld be supervised by [CONTACT_31588]/LAR/caregiver.
CONFIDENTIAL Page [ADDRESS_40694] be reported by [CONTACT_38910]/Shi re Medical Monitor 
within [ADDRESS_40695] awareness of the event. Note: The 24-hour reporting requirement for 
SAEs does not apply to reports of abuse, misuse, overdose, or m edication errors (Section 8.1.6) 
unless they result in an SAE.
The investigator must complete, sign, and date the Shire Clinical Study Serious Adverse Event 
and Nonserious AEs Required by [CONTACT_38911] (Note: Source documents are not to be sent unless requested) and fax or e-mail the form to the Shire Global Pharmacovigilance 
and Risk Management Department. A copy of the Shire Clinical Study Serious Adverse Event and Nonserious AEs Required by [CONTACT_10191] (and any applicable follow-up reports) must also be sent to the CRO/Shire Medical Monitor using the details  specified in the emergency 
contact [CONTACT_1739].
8.2.[ADDRESS_40696] medical occurrence (whether considered to  be related to investigational 
product or not) that at any dose:
Results in death
Is life-threatening. Note: The term “life-threatening” in the de finition of “serious” refers to an
event in which the subject was at risk of death at the time of the event; it does not refer to an
event which hypothetically might have caused death if it was mo re severe.
Requires inpatient hospi[INVESTIGATOR_1081]. Note:
Hospi[INVESTIGATOR_38859]-existing conditions and have not worsened after initiation o f treatment should not be
classified as SAEs. For example, an admission for a previously scheduled ventral hernia
repair would not be classified as an SAE; however, complication (s) resulting from a
hospi[INVESTIGATOR_38860](s) serious criteria
must be reported as an SAE(s).
Results in persistent or significant disability/incapacity
Is a congenital abnormality/birth defect
Is an important medical event. Note: Important medical events t hat may not result in
death, be life-threatening, or require hospi[INVESTIGATOR_38861], based
upon appropriate medical judgment, they may jeopardize the subj ect and may require
medical or surgical intervention to prevent 1 of the outcomes l isted in this definition.
CONFIDENTIAL Page 58 Shire
Protocol SHP465-112 15 Sep 2017
Examples of such medical events include allergic bronchospasm requiring intensive 
treatment in an emergency room or at home; blood dyscrasias or convulsions that do not 
result in inpatient hospi[INVESTIGATOR_059]; or the development of drug  dependency or drug abuse.
8.2.4 Serious Adverse Event Collection Time Frame
All SAEs (regardless of relationship to study) are collected fr om the time the subject signs the 
informed consent until the defined follow-up period stated in Section 7.1.[ADDRESS_40697] be reported 
to the Shire Global Pharmacovigilance and Risk Management Depar tment and the CRO/Shire 
Medical Monitor within [ADDRESS_40698] awareness of the event.
In addition, any SAE(s) considered “related” to the investigational product and discovered by [CONTACT_38912] [ADDRESS_40699]’s death (ie, the SAE was noted as the primary cause of death) 
must have “fatal” checked as an outcome with the date of death recorded as the resolution date. For all other events ongoing at the time of death that did not contribute to the subject’s death, the outcome should be considered not resolved, without a resolution date recorded.
For any SAE that results in the subject’s death or any ongoing events at the time of death, unless 
another investigational product action was previously taken (eg,  drug interrupted, reduced, or 
withdrawn), the action taken with the investigational product should be recorded as “dose not 
changed” or “not applicable” (if the subject never received investigational product). The investigational product action of “withdrawn” should not be sele cted solely as a result of the
subject’s death.
8.2.[ADDRESS_40700], Ethics Committee, and Site 
Reporting
The sponsor and the clinical CRO are responsible for notifying th e relevant regulatory authorities
and US central IRBs of related, unexpected SAEs.
In addition, the sponsor and clinical CRO are responsible for notif ying active sites of all related, 
unexpected SAEs occurring during all interventional studies acr oss the SHP465 program. 
CONFIDENTIAL Page 59 Shire
Protocol SHP465-112 15 Sep 2017
The investigator is responsible for notifying the local IRB, local ethics committee (EC), or the 
relevant local regulatory authority of all SAEs that occur at h is or her site as required.
9 DATA MANAGEMENT AND STATISTICAL METHODS
9.1 Data Collection
The investigators’ authorized site personnel must enter the inf ormation required by [CONTACT_38913]. A study monitor will visit each site i n accordance with the monitoring 
plan and review the CRF data against the source data for completeness and accuracy. 
Discrepancies between source data and data entered on the CRF w ill be addressed by [CONTACT_38914]. When a data discrepancy warrants correction, th e correction will be made by 
[CONTACT_1747]. Data collection procedures will be d iscussed with the site at the site 
initiation visit and/or at the investigator’s meeting. Once a s ubject is enrolled, it is expected that 
site personnel will complete the entries in the source document s within approximately [ADDRESS_40701]’s visit.
9.2 Clinical Data Management
Data are to be entered into a clinical database as specified in  the CRO’s data management plan. 
Quality control and data validation procedures are applied to e nsure the validity and accuracy of 
the clinical database.
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerized and manual procedures. Data qu eries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to the clinical database, and all corrections are documented in an  auditable manner.
9.3 Statistical Analysis Process
The study will be analyzed by [CONTACT_10196].
The statistical analysis plan (SAP) will provide the statistical methods and definitions for the 
analysis of the PK, pharmacodynamic, and safety data, as well as describe the approaches to be taken for summarizing other study information such as subject d isposition, demographics and 
baseline characteristics, investigational product exposure, and prior and concomitant medications. The SAP will also include a description of how mis sing, unused, and spurious data 
will be addressed.
To preserve the integrity of the statistical analysis and study  conclusions, the SAP will be 
finalized prior to database lock.
All statistical analyses will be performed using SAS
(SAS Institute, Cary, NC [ZIP_CODE]). 
CONFIDENTIAL Page 60 Shire
Protocol SHP465-112 15 Sep 2017
9.4 Planned Interim Analysis, Adaptive Design, and Data Monitoring Committee
There is no planned interim analysis or adaptive design in this  study.
9.4.1 Data Monitoring Committee
An external independent data monitoring committee (DMC) will be se t up for the following 
studies: SHP465-112, SHP465-308, and SHP465-309. The DMC will review the data pertaining 
to safety, tolerability, and benefit/harm of the study therapy.  Confidentiality of the unblinded 
DMC analyses is a critical concern and to address this, an unbl inded independent reporting team 
will be identified within a CRO. The independent reporting team will have no involvement in the conduct of the study. Further details regarding the DMC can be found in the DMC charter.
9.5 Sample Size Calculation and Power Considerations
To objectively justify the sample size for PK sampling and PK sampling scheme for this study, 
the following precision is recommended in the Food and Drug Adm inistration (FDA) guidance, 
General Clinical Pharmacology: Considerations for Pediatric Stu dies for Drugs and Biological 
Products ( DHHS, 2014).
The sample size for traditional rich PK sampling for noncompartm ental analysis is calculated to 
achieve 80% probabi lity (pow er), to assure the 95% confidence in terval of the point estimate of 
the geometric mean of clearance is within 60% to 140% of the es timate of the clearance. 
Although the range (60%, 140%) is not symmetric to 1, the lower  confidence interval bound is 
within (60%, 140%) (1/1.4=0.714), as long as the upper bound is ≤1.4.
The available data in Table 6 are from Shire’s completed study (SHP465-111) with an ADHD 
pediatric population and shows the reported apparent clearance (C L/F) and volume of 
distribution (V
z/F) for the d-amphetamine and l-amphetamine of SHP465 after oral 
administration of 12.5 mg in children aged 6 to 12 years and 25 m g in adolescents aged 
13 to 17 years.
Table 6: Estimates of Clearance and Volume of Distribution for G-Amphetamine and 
O-Amphetamine
CV (%)SHP465 12.5 mg
Children (6 to 12 years)SHP465 25 mg
Adolescents (13 to 17 years)
CL/F (L/h) V z/F (L) CL/F (L/h) V z/F (L)
d-Amphetamine 25.0 28.5 23.7 18.4
l-Amphetamine 26.9 32.2 28.4 22.0
CV=coefficient of variation  
Source: SHP465-[ADDRESS_40702] l-amphetamine variability of 32.2%, since it is 
numerically bigger. Applying the methods from the manuscript by W ang et al.,( 2012), sample 
size estimations with related probability for corresponding coe fficients of variation are provided 
as follows:
CV (%) Number of Subjects RequiredProbability of the Point Estimate 
Within the Prespecified Interval (%)
18.4 5 89
22.0 5 80
23.7 6 88
25.0 6 82
26.9 6 89
28.4 7 88
28.5 7 88
32.2 8 90
CV=coefficient of variation.
Based on these data, the PK analysis will need at least [ADDRESS_40703] of all subjects in the safety set for whom at leas t 1 postdose PK blood 
sample was collected.
9.7 Pharmacokinetic Analyses
9.7.1 Pharmacokinetic Analysis
All the PK analyses will be performed using the PK set.
Pharmacokinetic parameters will be determined from the plasma c oncentration-time data for 
d-amphetamine and l-amphetamine by [CONTACT_38875]
®WinNonlin®
(Certara, Princeton, NJ) Version 6.4 or higher.
CONFIDENTIAL Page 62 Shire
Protocol SHP465-112 15 Sep 2017
The PK parameters will include, but not be limited to:
AUC 0-∞ Area under the curve extrapolated to infinity
AUC 0-t Area under the curve from time [ADDRESS_40704] e collection
AUC 0-5 Area under the curve from time 0 predose to 5 hours postdose
AUC 5-t Area under the curve from time [ADDRESS_40705] time point of sample collection
AUC last Area under the curve from the time of dosing to the last measurable concentration
AUC tau Area under the concentration curve over the dosing interval (24 hours) at steady
state
CL/F Total body clearance for extravascular administration
Cmax Maximum concentration occurring at t max
Ctrough Trough plasma concentration (the predose concentrations collected at steady 
state)
t1/2 Terminal half-life
tmax Time of maximum observed concentration sampled during a dosing interval
VF/ss Apparent volume of distribution at steady state
Vz/F Volume of distribution associated with the terminal slope fol lowing extravascular 
administration
 z The first order rate constant associated with the terminal phas e of elimination
[IP_ADDRESS] Statistical Analysis of Pharmacokinetic Parameters
There will be no inferential statistical analysis of the PK data . Summary descriptive statistics 
(number of observations, mean, standard deviation, coefficient of variation, median, maximum, 
minimum and geometric mean) will be determined for all PK paramet ers. Plasma concentrations 
at each nominal sampling time will also be summarized using descriptive statistics.
9.8 Safety Analyses
Safety will be assessed by [CONTACT_38915], vital signs (systolic and dia stolic blood pressure, pulse rate, 
respi[INVESTIGATOR_697], and body temperature), 12-lead ECGs, weight, height, clinical laboratory tests 
(biochemistry, hematology, and urinalysis), PSQ, and a validate d sleep questionnaire (CSHQ).
Additionally, the C-SSRS will capture the safety of SHP465 rela ted to suicidality.
The safety endpoints will be summarized with descriptive statis tics for the safety set.
Relevant safety endpoints as well as their changes from baselin e will be summarized. 
Baseline is defined as the last assessment prior to the first dos e of investigational product. 
Potentially clinically important findings will also be summariz ed or listed. The potentially 
clinically important values will be defined in the SAP.
CONFIDENTIAL Page [ADDRESS_40706], AEs leading to 
withdrawal, SAEs, and deaths will be similarly summarized/liste d.
10 SPONSOR’S AND INVESTIGATOR’S RESPONSIBILITIES
This study is conducted in accordance with current applicable r egulations, ICH, and local ethical 
and legal requirements.
The name [CONTACT_38936] (eg, CRO) used in this study will be maintained 
in the investigator’s and sponsor’s files, as appropriate.
10.1 Sponsor’s Responsibilities
10.1.[ADDRESS_40707] been delegated will undertake their assigned roles for thi s study in compliance with all 
applicable industry regulations, ICH GCP Guideline E6 (1996) and  any updates, and all 
applicable national and local laws and regulations.
Visits to sites are conducted by [CONTACT_38916] s ponsor and/or the company 
organizing/managing the research on behalf of the sponsor to inspect study data, subjects’ 
medical records, and source documents in accordance with current  GCP and the respective local 
and inter/national government regulations and guidelines. Recor ds and data may additionally be 
reviewed by [CONTACT_38917].
The sponsor ensures that local regulatory authority requirement s are met before the start of the 
study. The sponsor (or a nominated designee) is responsible for  the preparation, submission, and 
confirmation of receipt of any regulatory authority approvals r equired prior to release of 
investigational product for shipment to the site.
10.1.2 Public Posting of Study Information
The sponsor is responsible for posting appropriate study inform ation on applicable websites. 
Information included in clinical study registries may include p articipating investigators’ names 
and contact [CONTACT_3031].
CONFIDENTIAL Page 64 Shire
Protocol SHP465-112 15 Sep 2017
10.1.3 Submission of Summary of Clinical Study Report to Competen t Authorities 
of Member States Concerned and Ethics Committees
The sponsor will provide a summary of the clinical study report  to the competent authority of the 
member state(s) concerned as required by [CONTACT_38918](s) and to comply with the 
Community guideline on GCP. This requirement will be fulfilled within 6 months of the end of 
the study completion date for pediatric studies and within 1 ye ar for nonpediatric studies as per 
guidance.
10.1.4 Study Suspension, Termination, and Completion
The sponsor may suspend or terminate the study, or part of the study, at any time for any reason. 
If the study is suspended or terminated, the sponsor will ensur e that applicable sites, regulatory 
agencies, and IRBs/ECs are notified as appropriate. Additionally , the discontinuation of a 
registered clinical study which has been posted to a designated  public website will be updated 
accordingly.
10.2 Investigator’s Responsibilities
10.2.[ADDRESS_40708] undertake to perform the study in accorda nce with ICH GCP Guideline E6 
(1996) and any updates, and applicable regulatory requirements a nd guidelines.
It is the investigator’s responsibility to ensure that adequate  time, resources, and appropriately 
trained personnel are available at the site prior to commitment to participate in this study. The 
investigator should also be able to estimate or demonstrate a potential for recruiting the required number of suitable subjects within the agreed recruitment perio d.
The investigator will maintain a list of appropriately qualifie d persons to whom the investigator 
has delegated significant study-related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any licenses and certifications necessar y to demonstrate such 
qualification. Curriculum vitae for investigators and subinvesti gators are provided to the study 
sponsor (or designee) before starting the study.
If a potential research subject has a primary care physician, t he investigator should, with the 
subject’s consent, inform them of the subject’s participation i n the study.
A co-ordinating principal investigator [INVESTIGATOR_38862]. Agreement with the final clinical study re port is documented by [CONTACT_38919]-ordinating principal investigator , in compliance with ICH 
Guideline E3 (1995).
10.2.[ADDRESS_40709] met 
protocol eligibility criteria. Investigators are required to si gn an investigator agreement to 
confirm acceptance and willingness to comply with the study pro tocol.
CONFIDENTIAL Page 65 Shire
Protocol SHP465-112 15 Sep 2017
If the investigator suspends or terminates the study at their s ite, the investigator will promptly 
inform the sponsor and the IRB/EC and provide them with a detai led written explanation. The 
investigator will also return all investigational product, cont ainers, and other study materials to 
the sponsor. Upon study completion, the investigator will provide the sponsor, IRB/EC, and 
regulatory agency with final reports and summaries as required by (inter)national regulations.
Communication with local IRBs/ECs, to ensure accurate and timel y information is provided at 
all phases during the study, may be done by [CONTACT_456], applic able CRO, investigator, or, for 
multicenter studies, the co-ordinating principal investigator, according to national provisions,and will be documented in the investigator agreement.
10.2.3 Documentation and Retention of Records
[IP_ADDRESS] Case Report Forms
Case report forms are supplied by [CONTACT_38920].
The investigator is responsible for maintaining adequate and ac curate medical records from 
which accurate information is recorded onto CRFs, which have been designed to record all 
observations and other data pertinent to the clinical investiga tion. Case report forms must be 
completed by [CONTACT_38921].
All data will have separate source documentation; no data will be recorded directly onto the 
CRF.
All data sent to the sponsor must be endorsed by [CONTACT_1188].
The CRA/study monitor will verify the contents against the sour ce data per the monitoring plan. 
If the data are unclear or contradictory, queries are sent for corrections or verification of data.
[IP_ADDRESS] Recording, Access, and Retention of Source Data and Stu dy Documents
Original source data to be reviewed during this study will include, but are not limited to: 
subject’s medical file, subject’s diary, and original clinical la boratory reports.
All key data must be recorded in the subject’s medical records.
The investigator must permit authorized representatives of the sponsor; the respective national, 
local, or foreign regulatory authorities; the IRB/EC; and auditor s to inspect facilities and to have 
direct access to original source records relevant to this study , regardless of media.
The CRA/study monitor (and auditors, IRB/EC, or regulatory inspe ctors) may check the CRF 
entries against the source documents. The consent form includes  a statement by [CONTACT_10203]/auditor from the sponsor or its r epresentatives, national or local 
regulatory authorities, or IRB/EC, having access to source data (eg, subject’s medical file, appointment books, original laboratory reports, X-rays, etc).
CONFIDENTIAL Page [ADDRESS_40710] be made available within reasonable times for inspection and duplication, if 
required, by a properly authorized representative of any regulatory agency (eg, the US FDA) or 
an auditor.
Essential documents must be maintained according to ICH GCP requirements and may not be 
destroyed without written permission from the sponsor.
[IP_ADDRESS] Audit/Inspection
To ensure compliance with relevant regulations, data generated by [CONTACT_38922], eg, the US F DA (as well as other US national 
and local regulatory authorities), other regulatory authorities , the sponsor or its representatives, 
and the IRB/EC for each site.
[IP_ADDRESS] Financial Disclosure
The investigator is required to disclose any financial arrangem ent during the study and for 1 year 
after, whereby [CONTACT_38923], or other payments the investigator receiv ed from the sponsor. The 
following information is collected: any significant payments fr om the sponsor or subsidiaries 
such as a grant to fund ongoing research, compensation in the f orm of equipment, retainer for 
ongoing consultation or honoraria; any proprietary interest in investigational product; any 
significant equity interest in the sponsor or subsidiaries as d efined in US Title 21 Code of 
Federal Regulations Part 54 2(b) (1998).
10.2.[ADDRESS_40711] at all times comply with all local, state , and national laws pertaining to 
registration and reporting with the appropriate  regulatory body  and control and handling of such 
substances.10.3 Ethical Considerations
10.3.1 Informed Consent/Assent
It is the responsibility of the investigator to obtain written informed consent and assent from all 
study subjects and their parent/LAR prior to any study-related procedures including screening 
assessments. All consent and assent documentation must be in acco rdance with applicable 
regulations and GCP. Each subject or the subject’s parent/LAR, as applicable, is requested to 
sign and date the subject informed consent form or a certified translation if applicable, after the subject has received and read (or been read) the written subject information and received an explanation of what the study involves, including but not limit ed to: the objectives, potential 
benefits and risk, inconveniences, and the subject’s rights and  responsibilities. A copy of the
informed consent and assent documentation (ie, a complete set of subject information sheets and 
fully executed signature [CONTACT_1787]) must be given to the subject or  the subject’s parent/LAR, as 
applicable. This document may require translation into the loca l language. Signed consent forms 
must remain in each subject’s study file and must be available for verification at any time.
CONFIDENTIAL Page 67 Shire
Protocol SHP465-112 15 Sep 2017
Within the source documents, site personnel should document instruction of and understanding 
by [CONTACT_7071]/LAR/caregiver of the safe, responsible storage and  administration of 
investigational product to the study subject.
The principal investigator [INVESTIGATOR_1682] a copy of the consent form and assent form
that was reviewed by [CONTACT_1201]/EC and received their favorable opi [INVESTIGATOR_1649]/approval. A copy of the 
IRB/EC’s written favorable opi[INVESTIGATOR_1649]/approval of these documents must be provided to the 
sponsor prior to the start of the study unless it is agreed to and documented (abiding by 
[CONTACT_1761]) prior to study s tart that another party (ie, sponsor 
or co-ordinating principal investigator) is responsible for thi s action. Additionally, if the 
IRB/EC requires modification of the sample subject information a nd consent document 
provided by [CONTACT_456], the documentation supporting this requirement must be provided to the sponsor.
10.3.[ADDRESS_40712] or Ethics Committee
It is the responsibility of the investigator to submit this pro tocol, the informed consent document 
(approved by [CONTACT_38924]), relevant supportin g information, and all types of 
subject recruitment information to the IRB/EC for review, and a ll must be approved prior to site 
initiation.
Responsibility for co-ordinating with IRBs/ECs is defined in th e clinical trial agreement.
Prior to implementing changes in the study, the sponsor and the  IRB/EC must approve any 
revisions of all informed consent documents and amendments to the protocol unless there is a 
subject safety issue.
Investigational product supplies will not be released until the  CRO has received written IRB/EC 
approval of and copi[INVESTIGATOR_10158].The investigator is responsible for keepi[INVESTIGATOR_1683]/EC appraise d of the progress of the study 
and of any changes made to the protocol, but in any case at least  once a year. The investigator 
must also keep the local IRB/EC informed of any serious and sig nificant AEs.
10.[ADDRESS_40713] (HIPAA) of 
1996. A site that is not a covered entity as defined by [CONTACT_38925].
The confidentiality of records that may be able to identify sub jects will be protected in 
accordance with applicable laws, regulations, and guidelines.
CONFIDENTIAL Page [ADDRESS_40714] consented/assented to take part in the study , the sponsor and/or its 
representative reviews their medical records and data collected during the study. These records 
and data may, in addition, be reviewed by [CONTACT_1774]: independent auditors 
who validate the data on behalf of the sponsor; third parties with whom the sponsor may develop, register, or market SHP465; national or local regulato ry authorities; and the IRB/EC 
which gave approval for the study to proceed. The sponsor and/or its representative accessing the records and data will take all reasonable precautions in accordance with applicable laws, regulations, and guidelines to maintain the confidentiality of subjects’ identities.
Subjects are assigned a unique identifying number; however, the ir initials and date of birth may 
also be collected and used to assist the sponsor to verify the accuracy of the data (eg, to confirm 
that laboratory results have been assigned to the correct subje ct).
The results of studies – containing subjects’ unique identifying number, relevant medical records, and possibly initials and dates of birth – will be recorded. They may be transferred to, and used in, other countries which may not afford the same leve l of protection that applies within 
the countries where this study is conducted. The purpose of any such transfer would include: to support regulatory submissions, to conduct new data analyses to  publish or present the study 
results, or to answer questions asked by [CONTACT_38926] a uthorities.
10.5 Study Results/Publication Policy
Shire will endeavor to publish the results of all qualifying, a pplicable, and covered studies 
according to external guidelines in a timely manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative. Additionally, Shire adheres to external guidelines 
(eg, Good Publication Practices 2) when forming a publication st eering committee. The purpose 
of the publication steering committee is to act as a noncommerc ial body that advises or decides 
on dissemination of scientific study data in accordance with th e scope of this policy.
All publications relating to Shire products or projects must undergo appropriate technical and intellectual property review, with Shire agreement to publish p rior to release of information. The 
review is aimed at protecting the sponsor’s proprietary information existing either at the commencement of the study or generated during the study. To the  extent permitted by [CONTACT_38927], the principal investigator [INVESTIGATOR_38863] n (or share with other authors) the 
copyright on his/her publications. To the extent that the princ ipal investigator has such sole, joint 
or shared rights, the principal investigator [INVESTIGATOR_10160]  a perpetual, irrevocable, 
royalty-free license to make and distribute copi[INVESTIGATOR_38864].
The term “publication” refers to any public disclosure including original research articles, review articles, oral presentations, abstracts and posters at medical congresses, journal supplements, 
letters to the editor, invited lectures, opi[INVESTIGATOR_10162], book chapters, electronic postings on medical/scientific websites, or other disclosure of the study r esults, in printed, electronic, oral, or 
other form.
CONFIDENTIAL Page [ADDRESS_40715] the right to publish 
the study results, and any background information provided by [CONTACT_38928], or necessary for o ther scholars to verify such study 
results. Notwithstanding the foregoing, no publication that incorporates the sponsor’s confidential information shall be submitted for publication wit hout the sponsor’s prior written 
agreement to publish, and shall be given to the sponsor for review at least [ADDRESS_40716] publicat ion of the study results shall be made 
by [CONTACT_10208]’s presentation of a joint, multicenter publication 
of the compi[INVESTIGATOR_38865]. If such a multicente r publication is not submitted to a 
journal for publication by [CONTACT_10209] 18-month perio d after conclusion, abandonment, 
or termination of the study at all sites, or after the sponsor confirms there shall be no multicenter 
study publication of the study results, an investigator may ind ividually publish the study results 
from the specific site in accordance with this section. The inv estigator must, however, 
acknowledge in the publication the limitations of the single-site data being presented.
Unless otherwise required by [CONTACT_38929], or the forum in which 
it is made, authorship will comply with the International Committee of Medical Journal Editors 
current standards. Participation as an investigator does not co nfer any rights to authorship of 
publications.
CONFIDENTIAL Page 70 Shire
Protocol SHP465-112 15 Sep 2017
11 REFERENCES
Arnsten AF 2001. Modulation of prefrontal cortical-striatal circ uits: relevance to therapeutic 
treatments for Tourette syndrome and attention-deficit hyperact ivity disorder. Adv Neurol; 
85:333-41.
Bhutta AT, Anand KJ 2002. Vulnerability of the developi[INVESTIGATOR_38866].  Neuronal mechanisms. Clin 
Perinatol; 29(3) :357-72.
Brown K 2003. Neuroscience. New attention to ADHD genes. Science; 301(5630) :160-1.
Brown T 1996. Attention-Deficit Disorder Scales for Adolescents and Adults. The Psychological 
Corporation: San Antonio (TX).
Buitelaar JK, Michelson D, Danckaerts M, Gillberg G, Spencer TJ, Zuddas A, et al. 2007, A 
randomized, double-blind study of continuation treatment for att ention-deficit/hyperactivity 
disorder after 1 year. Biol Psychiatry ; 61(5):694-9.
Döpfner M, Steinhausen HC, Coghill D, Dalsgaard S, Poole L, Ralston SJ, et al. 2006. Cross-cultural reliability and validity of ADHD assessed by [CONTACT_38930] a 
pan-European study. Eur Child Adolesc Psychiatry ; 15(Suppl 1):146-55.
DuPaul GJ, Power TJ, Anastopoulos AD, Reed R 2016. ADHD rating scale-5 for children and 
adolescents: checklists, norms, and clinical interpretation. Guilford Press: [LOCATION_001].
Greenfield B, Hechman L 2005. Treatment of attention deficit hyper activity disorder in adults. 
Expert Rev Neurother; 5(1):107-21.
Guy W. editor 1976. Clinical Global Impression (CGI) . In: ECDEU Assessment Manual for 
Psychopharmacology . US Department of Health, Education, and Welfare. Rockville, M D, 
217-22.
Heal DJ, Smith SL, Gosden J, Nutt DJ 2013. Amphetamine, past and  present – a 
pharmacological and clinical perspective. J Psychopharmacol ; 27(6):479-96.
Kahn RS, Khoury J, Nichols WC, Lanphear BP 2003. Role of dopamin e transporter genotype 
and maternal prenatal smoking in childhood hyperactive-impulsiv e, inattentive, and oppositional 
behaviors. J Pediatr; 143(1):104-10.
Kratochvil CJ, Bohac D, Harrington M, Baker N, May D, Burke, WJ  2001. An open-label trial of 
tomoxetine in pediatric attention deficit hyperactivity disorde r. J Child Adolesc 
Psychopharmacol ; 11(2):167-70.
Kratochvil CJ, Vaughan BS, Harrington MJ, Burke WJ 2003. Atomoxet ine: a selective 
noradrenaline reuptake inhibitor for the treatment of attention -deficit/hyperactivity disorder. 
Expert Opin Pharmacother ; 4(7):1165-74.
CONFIDENTIAL Page 71 Shire
Protocol SHP465-112 15 Sep 2017
Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee  FR. et al. 2001. Atomoxetine 
in the treatment of children and adolescents with attention-def icit/hyperactivity disorder: a 
randomized, placebo-controlled, dose-response study. Pediatrics ; 108(5):E83.
National Institutes of Health (NIH) 2004. The fourth report on t he diagnosis, evaluation, and 
treatment of high blood pressure in children and adolescents. Pediatrics ; 114([ADDRESS_40717] 4th 
report):555-76.
Ostchega Y, Porter KS, Hughes J, Dillon CF, Nwankwo T 2011. Resting pulse rate reference 
data for children, adolescents, and adults: [LOCATION_002], 1999 -2008. Natl Health Stat Report;
(41):1-16.
Posner K 2007. Suicidality Issues in Clinical Trials: Columbia Suicidal Adverse Event 
Identification in FDA Safety Analyses Division of Metabolism an d Endocrinology Products 
Advisory Committee Meeting, Food and Drug Administration.
Safren SA, Sprich S, Chulvick S. Otto MW 2004. Psychosocial trea tments for adults with 
attention-deficit/hyperactivity disorder. Psychiatr Clin North Am ; 27(2):349-60.
Sheehan DV, Sheehan KH, Shytle RD, Janavs J, Bannon Y, Rogers JE, et al. 2010. Reliability 
and validity of the Mini International Neuropsychiatric Intervi ew for Children and Adolescents 
(MINI-KID). J Clin Psychiatry ; 71(3):313-26.
Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griff in S 1996. Pharmacotherapy 
of attention-deficit hyperactivity disorder across the life cyc le. J Am Acad Child Adolesc 
Psychiatry ; 35(4):409-32.
Spencer T, Biederman J, Heiligenstein J, Wilens T, Faries D, Prince J, et al. 2001 An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol; 11(3):251-65.
US Department of Health and Human Services (DHHS), Food and Drug Administration, Center 
for Drug Evaluation and Research (CDER). Draft guidance. Guidan ce for industry. General 
clinical pharmacology considerations for pediatric studies for d rugs and biological products.
Dec 2014.Wang Y, Zheng Y, Du Y, Song DH, Shin YJ, Cho SC, et al. 2007. A tomoxetine versus 
methylphenidate in paediatric outpatients with attention defici t hyperactivity disorder: a 
randomized, double-blind comparison trial. Aust N Z J Psychiatry ; 41(3):222-30.
Wang Y, Jadhav PR, Lala M, Gobburu JV 2012. Clarification on pr ecision criteria to derive 
sample size when designing pediatric pharmacokinetic studies. J Clin Pharmacol ; 
52(10):1601-6.Weiss M, Murray C 2003. Assessment and management of attention-def icit hyperactivity 
disorder in adults. CMAJ ; 168(6):715-22.
CONFIDENTIAL Page 72 Shire
Protocol SHP465-112 15 Sep 2017
Weiss M, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, Thomason C, et al. 2005. A 
randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children 
with ADHD. J Am Acad Child Adolesc Psychiatry ; 44(7):647-55.
Wilens TE, Spencer TJ, Biederman J, Girard K, Doyle R, Prince J , et al. 2001. A controlled 
clinical trial of bupropi[INVESTIGATOR_38867]. Am J Psychiatry ;
158(2):282-8.
Wilens TE, Spencer TJ, Biederman J 2002. A review of the pharmaco therapy of adults with 
attention-deficit/hyperactivity disorder. J Atten Disord ; 5(4):189-202.
CONFIDENTIAL Page 73 Shire
Protocol SHP465-112 15 Sep 2017
12 APPENDICES
CONFIDENTIAL Page 75 Shire
Protocol SHP465-112 15 Sep 2017
APPENDIX 2 DIAGNOSTIC CRITERIA/DISEASE CLASSIFICATION
APPENDIX 2.1 DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL 
DISORDERS, FIFTH EDITION CRITERIA
A. Either (1) or (2):
(1) six (or more) of the following symptoms of inattention have persisted for at least 
6 months to a degree that is maladaptive and inconsistent with d evelopmental level:
Inattention
a) often fails to give close attention to details or makes careless mistakes in
schoolwork, work or other activities
b) often has difficulty sustaining attention in tasks or play ac tivities
c) often does not seem to listen when spoken to directly
d) often does not follow through on instructions and fails to fi nish schoolwork,
chores, or duties in the workplace (not due to oppositional beh avior or failure to
understand instructions)
e) often has difficulty organizing tasks and activities
f) often avoids, dislikes, or is reluctant to engage in tasks that require sustained
mental effort (such as schoolwork or homework)
g) often loses things necessary for tasks or activities (eg, toy s, school assignments,
pencils, books, or tools)
h) is often easily distracted by [CONTACT_38931]
i) is often forgetful in daily activities
(2) six (or more) of the following symptoms of hyperactivity-impulsivity have 
persisted for at least 6 months to a degree that is maladaptive and inconsistent with 
developmental level:
Hyperactivity
(a) often fidgets with hands or feet or squirms in seat(b) often leaves seat in classroom or in other situations in which remaining seated is 
expected
(c) often runs about or climbs excessively in situations in whic h it is inappropriate 
(in adolescents or adults, may be limited to subjective feeling s of restlessness)
(d) often has difficulty playing or engaging in leisure activiti es quietly
(e) is often “on the go” or often acts as if “driven by a motor”(f) often talks excessively
CONFIDENTIAL Page 76 Shire
Protocol SHP465-112 15 Sep 2017
Impulsivity
(g) often blurts out answers before questions have been complete d
(h) often has difficulty awaiting turn
(i) often interrupts or intrudes on others (eg, butts into conversations or games)
B. Several inattentive or hyperactive-impulsive symptoms were p resent prior to age 
12 years.
C. Several impairments from the symptoms are present in 2 or mo re settings (eg, at school 
[or work] and at home).
D. There is clear evidence of clinically significant impairment  in social, academic, or 
occupational functioning.
E. The symptoms do not occur exclusively during the course of a Pervasive Development 
Disorder, Schizophrenia, or other Psychotic Disorder and are no t better accounted for 
by [CONTACT_38932] (eg, Mood Disorder, Anxiety Disorder , Dissociative 
Disorder, or a Personality Disorder).
Code based on type:
314.01 Attention-Deficit/Hyperactivity Disorder, Combined Type: if both Criteria A1 and A2 
are met for the past 6 months
314.00 Attention-Deficit/Hyperactivity Disorder, Predominately Inattentive Type: if 
Criterion A1 is met but Criterion A2 is not met for the past 6 months
314.01 Attention-Deficit/Hyperactivity Disorder, Predominately H yperactive-Impulsive 
Type: if Criterion A2 is met but Criterion A1 is not met for the past 6 months
From the Diagnostic and Statistical Manual of Mental Disorders,  Fifth Edition. Copyright 2013 
American Psychiatric Association.
CONFIDENTIAL Page 77 Shire
Protocol SHP465-112 15 Sep 2017
APPENDIX 2.2 BOYS’ STATURE-FOR-AGE AND WEIGHT-FOR-AGE 
PERCENTILES
 
 
 
 
 
 
 
 
 
 
 
 
         
       
         
    
     
           
         
      
 
 
 
 
   
 
 
  
  
  
  
  
  
   
  
  
   
  
  
 
  
   
 
  
  
   
 
     
 
   
 
 
  
  
 
 
 
  
 
 
 
 
 
    
  
   
 
 
  
  
 
 
 
 
 
 
   
   
   
  
 
  
 
  
  
 
 
 
  
 
 
   
 
 
 
 
          
           
       
            
           
  
CONFIDENTIAL Page [ADDRESS_40718] for entry in the  study (based on the study inclusion 
criteria), first determine the percentile of height for the subject based on their age (as a whole 
number based on the subject’s last birthday; Appendix 2.2 ). For subjects who fall between the 
[ADDRESS_40719]’s age and height percentile for age are determined, use the following table to det ermine eligibility.
All blood pressure values listed as follows are 95th percentile for age and height percentile. The subject’s systolic and diastolic blood pressure readings at the  screening visit and the baseline 
visit (predose on Day 1) must not exceed the following correspo nding table value for their age 
and height percentile.
Age 
(Year)Systolic Blood Pressure (mmHg) Diastolic Blood Pressure (mmHg)
Percentile of Height  Percentile of Height 
5% 10% 25% 50% 75% 90% 95% 5% 10% 25% 50% 75% 90% 95%
4 106 107 109 111 112 114 115 66 67 68 69 70 71 71
5 108 109 110 112 114 115 116 60 70 71 72 73 74 74
6 109 110 112 114 115 117 117 72 72 73 74 75 76 76
Source: National Heart Lung and Blood Institute; May 2004
http://www nhlbi nih.gov/guidelines/hypertension/child_tbl.htm 
CONFIDENTIAL Page 79 Shire
Protocol SHP465-112 15 Sep 2017
APPENDIX 2.4 GIRLS’ STATURE-FOR-AGE AND WEIGHT-FOR-AGE 
PERCENTILES
 
 
 
  
 
 
 
 
 
 
 
         
    
    
     
          
           
     
 
  
  
  
  
  
 
  
  
  
  
  
 
  
  
 
 
  
 
  
  
  
 
  
   
 
       
    
    
 
 
  
 
 
   
    
  
   
 
 
 
   
 
  
 
  
  
 
  
   
   
 
   
  
  
  
 
 
 
  
 
   
  
  
   
 
 
 
          
           
      
            
           
  
    
CONFIDENTIAL Page [ADDRESS_40720] for entry in t he study (based on the study 
inclusion criteria), first determine the percentile of height for the subject based on their age (as a 
whole number based on the subject’s last birthday; Appendix 2.4). For subjects who fall between 
the [ADDRESS_40721]’s age and height 
percentile for age are determined, use the following table to det ermine eligibility.
All blood pressure values listed as follows are 95th percentile f or age and height percentile. The 
subject’s systolic and diastolic blood pressure readings at the  screening visit and the baseline 
visit (predose on Day 1) must not exceed the following corresponding table value for their age and height percentile.
Age 
(Year)Systolic Blood Pressure (mmHg) Diastolic Blood Pressure (mmHg)
Percentile of Height  Percentile of Height 
5% 10% 25% 50% 75% 90% 95% 5% 10% 25% 50% 75% 90% 95%
4 105 106 107 108 110 111 112 68 68 69 70 71 71 72
5 107 107 108 110 111 112 113 70 71 71 72 73 73 74
6 108 109 110 111 113 114 115 72 72 73 74 74 75 76
Source: National Heart Lung and Blood Institute; May 2004
http://www nhlbi nih.gov/guidelines/hypertension/child_tbl.htm 
CONFIDENTIAL Page 81 Shire
Protocol SHP465-112 15 Sep 2017
APPENDIX 3 SCALES AND ASSESSMENTS
The following scales/assessments will be utilized in this study :
Full Title of Scale/Assessment Version Number Date Issued
ADHD-RS-5 N/A 2016
CGI-I and CGI-S N/A [ADDRESS_40722] Visit 23 Jun 2010
CSHQ N/A 2009
MINI-KID 7.0.2 08 Aug 2016
PSQ N/A N/A
ADHD-RS-5=Attention-Deficit/Hyperactivity Disorder Rating Scale -5; CGI-I=Clinical Global 
Impressions - Improvement; CGI-S=Clinical Global Impressions – Sev erity of Illness; CSHQ=Children’s Sleep 
Habits Questionnaire; C-SSRS=Columbia-Suicide Severity Rating S cale; MINI-KID=Mini International 
Neuropsychiatric Interview for Children and Adolescents; N/A=no t applicable; PSQ=Post Sleep Questionnaire.
A separate master file containing each scale/assessment listed in the previous table will be 
provided to the site. Updates to scales/assessments during the study (if applicable) will be 
documented in the previous table, and a new master file containing  the revised scale/assessment 
will be provided to the site.